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Summary 
The role of endogenous neural stem cells (eNSCs) in metabolic syndrome and aging 
 
Introduction 
The adult brain exhibits low regenerative ability. Stem cell-based transplantation approaches 
have been largely unsuccessful, due to the difficulty to recapitulate the complex 
cytoarchitecture of the central nervous system (CNS). eNSCs are a new therapeutic option 
as pharmacological activation and increase of their number in vivo is accompanied by 
powerful neuroprotection in various disease models.  
Hes3 is expressed in both proliferating and quiescent NSCs, which makes it a useful 
biomarker for NSC identification. Direct injections of insulin in the adult brain increase the 
number of eNSCs and promote rescue of injured neurons via a novel molecular mechanism, 
the STAT3-Ser/Hes3 Signaling Axis. This molecular pathway with the STAT3-Ser 
phosphorylation at its core regulates Hes3 and together they form a merging point for several 
signals including insulin receptor activation.	
	
Main aim and Hypothesis 
Beyond the brain, STAT3-Ser/Hes3 signaling regulates various plastic cell populations in 
other organs of the endocrine/neuroendocrine system. In the pancreas, Hes3 is expressed in 
islets cells and regulates their growth, regeneration, and insulin release. Hes3 is also 
expressed in mouse hypothalamic tanycytes, which are diet responsive cells and play a very 
crucial role for the communication between the brain and the endocrine system. Also, Hes3 
is expressed in the adrenal gland (both in the cortex and medulla); cultured adrenal 
progenitors express Hes3 and various treatments that induce Hes3 expression promote their 
growth. Therefore, STAT3-Ser/Hes3 Signaling may be involved in tissue problems that result 
from metabolic dysfunction. 
Metabolic syndrome often results in diabetes (Type I, Type II) and insulin resistance, 
suggesting that eNSCs may be affected by the condition. There is evidence that obesity 
induces inflammatory reactions in the hypothalamus, leading to NSC loss. However, it is not 
clear if damage to NSCs is also directly linked to insulin signaling disruption. 
Materials and Methods 
In vivo animal models: For the aging experiments, mice were kept under normal diet 
conditions and were sacrificed in certain timepoints. Type I diabetes was induced by 1 single 
injection of high dose streptozotocin (STZ). Type II diabetes was induced by High Fat Diet 
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(HFD) administration. Metformin was administered in the drinking water. In vitro NSC 
cultures: Fetal Neural Stem Cells (fNSCs) were isolated and cultured from mouse embryos 
at embryonic day 13.5 (E13.5) and grown under established conditions for NSC 
maintenance. To assess possible effects of common pharmacological treatments prescribed 
for metabolic related dysfunctions on NSCs we treated the cultures with metformin and 
exendin-4. Proliferation was assessed by EdU incorporation. Cells were studied in their self-
renewal state and their differentiation potential into different cell types was also assessed 
following mitogen withdrawal from the cell culture medium. Immunocytochemistry-
Biochemistry: Standard immunofluorescence, X-gal staining techniques and Western 
Blotting were used to investigate protein expression changes in the genes of interest. 
Molecular Biology: PCR and qPCR were used to assess mRNA expression levels in the 
genes of interest. Phenotypic Analysis: Phenotypic characterization experiments were 
performed in house and through collaboration with the German mouse Clinic (GMC) in 
Munich.  
 
Results 
Our results show that various parameters affect Hes3 levels in the brain. Aging decreased 
Hes3 mRNA expression. Type I diabetes increased Hes3 expression. Type II diabetes 
decreased Hes3 expression. Thus, we conclude that eNSCs are modulated by diabetes in an 
age-dependent manner. 
We also investigated whether common medication for metabolic related dysfunction also 
affects Hes3 expression in the adult brain. Indeed, our results show that metformin 
decreases Hes3 expression in the mouse hypothalamus.  
To address whether metformin has a direct effect on NSCs we treated primary mouse fNSCs 
with metformin. Metformin decreases cell number, proliferation and affects cell morphology, 
giving a more differentiated appearance (large, flat cell body with wider projections). Hes3 
expression increases significantly at 72 hours of treatment.  
The metformin result opens the question if the increase in the Hes3 expression is a direct 
effect of the signal transduction pathways activated by metformin or due to a stress reaction. 
To address this we treated NSCs with exendin-4, another diabetes drug that we previously 
showed to both elevate Hes3 expression and cell number using a mouse insulinoma cell line 
(MIN6). Exendin-4 increases fNSC cell number but it did not affect the morphology. Similar to 
metformin proliferation was not affected. Hes3 expression increased significantly at 72 hours 
of treatment as well. This result indicates the distinctive action of the drugs on the STAT3-
Ser/Hes3 signaling pathway. Specifically it dissociates Hes3 levels from other cellular 
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parameters. Importantly it shows that two common diabetes medications have very different 
effects on NSCs.  
Because Hes3 is strongly regulated by metabolic parameters and medication we addressed 
potential roles of Hes3 using an established Hes3 null mouse line. Hes3 null mice exhibit no 
obvious phenotypes under normal conditions. However, we previously showed that when 
stressed by chemical induced damage, they exhibit low regenerative potential in the 
pancreas and brain. To identify additional phenotypes, we performed a phenotypic analysis 
of the Hes3 null mouse line under normal diet and HFD conditions (which induced type II 
diabetes). We found mild phenotypes that relate to the nervous system, the immune system 
and metabolism. At the molecular level, Hes3 deletion affects the expression of other genes 
within the Hes superfamily in the adult mouse brain. However, we did not observe these 
molecular differences in the HFD condition, suggesting an interplay between metabolic 
parameters (possibly, circulating insulin) and the regulation of Hes/Hey genes in the brain. 
Our data suggest a broad range of roles for Hes3, particularly under abnormal conditions.  
 
Conclusions 
Our work establishes that multiple parameters of metabolic state as well as diabetes 
medication affect Hes3 expression in the brain. Metabolic syndrome is a risk factor for many 
neurological disorders such as Alzheimer’s disease, Parkinson’s disease and Multiple 
Sclerosis. It is important to understand at the molecular and cellular level how metabolic 
dysfunction affects the brain. Here, we introduced a new cellular biomarker and signaling 
component that is greatly regulated in metabolic dysfunction.  
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Zusammenfassung  
Die Rolle endogener neuraler Stammzellen (eNSZs) im metabolischen Syndrom und in 
Alterungsprozessen 
 
Einleitung 
Die geringe Regenerationsfähigkeit des erwachsenen Gehirns verursacht zahlreicher 
neurologischer Erkrankungen. Aufgrund der komplizierten zellulären Architektur des 
Zentralnervensystems erwiesen sich dabei rasch auch moderne Therapieansätze wie 
Stammzelltransplantation weitgehend als erfolglos. Neue Hoffnung ruht derzeit auf dem 
gezielten Einsatz endogener neuraler Stammzellen (eNSZs), bei deren pharmakologische 
Aktivierung und Vermehrung in vivo bereits in diversen Krankheitsmodellen eine 
neuroprotektive Wirkung zeigte. 
In jüngster Forschung zeigte sich Hes3 durch seine Expression in sowohl proliferierend wie 
auch quieszente NSZs als idealer Biomarker zur Identifizierung von NSZs. Bedeutend dabei 
war die Etablierung der STAT3-Ser/Hes3 Signalachse, welche Aktivierung mittels einer 
lokalen Injektion von Insulin zu einem direkten zahlenmäßigen Anstieg der eNSZs und 
gleichzeitiger Verheilung verletzter Neuronen führte.  
	
Hypothese 
Zusätzlich zu seiner Rolle im Gehirn reguliert der STAT3-Ser/Hes3 Signalweg eine Vielzahl 
plastischer Zellpopulation des endokrinen/neuroendokrinen Systems. So wird Hes3 
beispielsweise von den Inselzellen des Pankreas exprimiert und beeinflusst deren 
Wachstum, Regeneration und Insulinsekretion.  
Desweiteren produzieren hypothalamische Maus-Tanyzyten Hes3  nahrungs-sensorische 
Zellen, die als eine entscheidende Schrittstelle in der Kommunikation zwischen Hirn und 
endokrinem System gelten. Ferner wird Hes3 in der Nebenniere und in der 
Nebennierenrinde als auch in der Medulla exprimiert; sowie in Nebennierenvorläuferzellen in 
Kulturen, deren Wachstum von Hes3-stimulierende Behandlungen verstärkt wird. 
Zusammenfassend betrachtet führt dies uns zu der Annahme,  dass der STAT3-Ser/Hes3 
Signalweg eine bedeutende Rolle bei Problemen auf organweiter Ebene spielt, welche von 
einer metabolischen Dysfunktion ausgelöst wird. 
Diabetes Typ 1 und Typ 2 (Insulinresistenz) sind zwei Krankheitsbilder des metabloschen 
Sydroms bei denen eNSZs in diesem Zustand vermutlich  betroffen sind. Es gibt Beweise, 
dass inflammatorische Reaktionen im Hypothalamus zum Verlust der NSC führen können. 
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Ob das Absterben der NSCs jedoch als eine direkte Konsequenz der gestörten Insulin-
Kaskade gilt, bleibt derzeit ungeklärt.  
 
Materialen und Methoden 
In vivo Tiermodelle. Alle Mäuse der Alterungsexperimente erhielten normal-kalorisches 
Standardfutter und wurden zu verschiedenen Zeitpunkten aufgegeben. Typ 1 Diabetes 
wurde durch eine einzige, hochdosierte Injektion von Streptozotocin (STZ) ausgelöst, Typ 2 
Diabetes durch Einnahme einer fettreichen Diät (60% Fett, zu Englisch High Fat Diet, kurz 
HFD). Metformin wurde durch Trinkwasser verabreicht. In vitro NSZ Kulturen: Fetale 
neurale Stammzellen wurden von Mausembryonen am Tag 13.5 isoliert und unter bereits 
etablierten Bedingungen zur NSC-Erhaltung kultiviert. Um den direkten Effekt klassischer 
Pharmazeutika zur Behandlung metabolischer Erkrankungen auf NSZs zu analysieren 
wurden die so gewonnen Zellkulturen mit Metformin und Exenatid  stimuliert. Die 
Proliferationsrate wurde dabei mittels EdU- Inkorporation festgestellt. Die Zellen wurden in 
ihrem eigenen  Erneuerungszustand untersucht. Weiterhin wurde ihre  
differenzierungspotential in anderen Zelltypen auch durch  Entnahme von Mitogenen vom 
der mittleren Zellkultur beurteilt. Immunzytochemie/Biochemische Methoden: 
Standardmethoden der Immunfluoreszenz, X-Gal Färbung und Western Blot Analyse wurden 
festellung den Änderungen der Proteinexpression des Zielgens verwendet. 
Molekularbiologische Methoden: Die Transkriptionsrate des Zielgens auf mRNA Level 
wurde mittels PCR und qPCR bestimmt. Phänotypische Analysen: Phänotypische 
Charakterisierungen wurden von uns in Zusammenarbeit mit unserer Kollegen des German 
Mouse Clinic (GMC) in München durchgeführt. 
 
Ergebnisse 
Aus unseren Daten geht hervor dass die Hes3- Level im Gehirn von diversen Parametern 
beeinflusst werden konnten. So führte Altern allein zu einer reduzierten Hes3-Expression auf  
mRNA Ebene, Typ 1 Diabetes jedoch zu einem Anstieg. Typ II Diabetes vermindert Hes3 
Expression auf mRNA. Folglich schließen wir dass die eNSZs durch Diabetes zeitabhängig 
moduliert werden. 
Zusätzlich beantworten wir  die Frage inwieweit traditionell verschriebene Medikamente zur 
Behandlung metabolischer Dysfunktionen einen Einfluss auf die He3s-Expressionsrate im 
Hirn eine Rolle spielt. Tatsächlich konnte es gezeigt werden, dass die Verabreichung von 
Metformin im Mausmodell zur einer Reduktion der Hes3-Expressionsrate im Hypothalamus 
führte. Darauf aufbauend untersuchten wir den direkten Einfluss von Metformin auf primären 
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Maus-fNSZs in Zellkulturen. Die Gabe von Metformin reduzierte dabei die Zellanzahl, die 
Proliferation und führte zu einem veränderten Zellerscheinungsbild: die Zellen zeigten eine 
generell differenzierte Morphologie mit einem breiteren und flacheren Zellkörper mit weiteren 
Zellvorsprüngen. Die Hes3-Expressionsrate stieg jedoch signifikant nach 72h.  
Die Ergebnisse unserer Metformin-Experimente führten uns zu der Fragestellung ob die 
gesteigerte Hes3-Expressionrate ein direkter Effekt der durch Metformin aktivierten 
Signaltransduktionwege oder eher eine Stressreaktion darstellte. Daraufhin inkubierten wir 
NSZs mit Exenatid, eine andere Routine Medikament zur Behandlung von Diabetes. In de 
Vorangegangenen Studie unserer Arbeitsgruppe mit MIN6, einer Maus-Insulinomazelllinie, 
konnte es gezeigt werden dass Exenatid zu einem Anstieg in Zellzahl und Hes3-
Expressionsrate führte. Die Proliferationsrate in NSZ-Kulturen war unverändert und die 
Hes3-Expression stieg signifikant nach 72h. Die Erhöhung von  Exenatid vermehrt die 
Zellzahl, jedoch ohne Einfluss auf die Morphologie. Dies weist darauf hin dass beide 
Medikamente auf verschiedenen Wegen die STAT3-Ser/Hes3-Achse wirken. Insbesondere  
unterschiedet sich Hes3-Ebenen von anderen zellulären Parametern. Vor allem betont dies 
jedoch welchen unterschiedlichen Effekt zwei herkömmlich verwendete 
Diabetesmedikamente auf NSZs ausüben können.  
Aufgrund den Hinweise auf Hes3 Regulation von metabolischen Parametern und Medikation, 
untersuchten wir abschließend die Rolle von Hes3 mittels einer etablierten Hes3-Null- 
Mauslinie. Unter normalen Bedingungen zeigen sich Hes3-Null-Mäuse keinerlei 
offensichtliche phänotypische Veränderungen. Frühere Arbeiten unserer Gruppe konnten 
jedoch zeigen dass diese Mäuse unter chemischen-induzierten Stress ein geringeres 
Regenerationspotential im Pankreas und Gehirn aufweisen. Um weitere Auffälligkeiten zu 
Nachweisen führten wir eine phänotypische Analyse von Hes3-Null-Mäusen unter 
Normaldiät und HFD (als Typ 2 Diabetes–Modell) durch. Dabei fanden wir milde Phänotypen 
in Verbindung mit dem Nervensystem, dem Immunsystem und Metabolismus unter 
Normaldiät. Auf molekularer Ebene übte die Hes3-Deletion Einfluss insbesondere auf andere 
Gene der Hes-Superfamilie im Maushirn aus. Interessanterweise konnten wir diese 
Unterschiede nicht mehr nach Fütterung der HFD nachweisen, was ein Zusammenspiel 
metabolischer Faktoren (möglicherweise zirkulierendes Insulin) und der Regulierung der 
Hes/Hey Gene im Hirn vermuten lässt. Zusammenfassend zeigen unsere Daten ein breites 
Rollenspektrum von Hes3, insbesondere unter pathologischen Bedingungen.  
 
Fazit 
Unsere Arbeit stellt fest, dass mehrere Parameter des metabolischen Zustands sowie 
Diabetes Medikamente Hes3-Expression im Gehirn beeinflussen. Im Vordergrund steht das 
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metabolische Syndrom einen als die Ursache für neurologische Erkrankungen wie 
Alzheimer-Krankheit, Parkinson-Krankheit und Multiple Sklerose. Daher ist ein tieferes 
Verständnis davon, wie metabolische Erkrankungen sowohl auf der molekularen wie auch 
zellulären Ebene unser Gehirn beeinflussen von absoluter Dringlichkeit notwendig. In dieser 
Studie etablieren wir einen neuen zellulären Biomarker und eine Signalkomponente, die 
durch metabolische Dysfunktion reguliert wird.  
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1 Introduction 
The adult brain exhibits low regenerative ability. Stem cell-based transplantation approaches 
have been largely unsuccessful, due to the difficulty to recapitulate the complex 
cytoarchitecture of the central nervous system (CNS). Endogenous neural stem cells 
(eNSCs) are a new therapeutic option as pharmacological activation and increase of their 
number in vivo is accompanied by powerful neuroprotection in various disease models 
(Androutsellis-Theotokis et al., 2006; Androutsellis-Theotokis et al., 2009; Dietrich and 
Kempermann, 2006; Emsley et al., 2005; Sun, 2014). This avoids the problems inherent with 
grafting, the problem of regenerating complex neuronal circuits, and reveals a new function 
of eNSCs, that of neuroprotection. 
Direct injection of insulin into the brain increases the number of eNSCs and promotes the 
rescue of injured dopamine neurons in the adult brain through a novel signaling pathway 
called the STAT3-Ser/Hes3 signaling axis (Androutsellis-Theotokis et al., 2006; 
Androutsellis-Theotokis et al., 2008). STAT3-Ser regulates Hes3, and together they form a 
convergence point for several signals, including Notch, Tie2, and insulin receptor activation 
(Poser et al., 2013). Hes3 is expressed in both proliferating and quiescent NSCs, which 
makes it an exceptional biomarker for NSC identification. 
Metabolic syndrome often results in diabetes (Type I, Type II) and insulin resistance, 
suggesting that eNSCs may be affected by the condition. There is evidence that obesity 
induces inflammatory reactions in the hypothalamus, leading to neural stem cell loss 
(Livesey, 2012).This may be independent of the insulin dysregulation but it may also involve 
insulin effects. 
In this part of my thesis, an overview of the literature relevant to the work is presented. 
Initially we introduce adult neurogenesis (historically, the observation that lead 
neuroscientists realize that there must be an adult eNSC population) followed by a 
comparison of therapeutic strategies involving cell replacement through cell grafting and 
those that involve the activation of endogenous NSCs. Then, the STAT3-Ser/Hes3 signaling 
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axis is presented in greater detail and in the context of inducing the activation of eNSC and 
neuroprotection. Lastly, we introduce the interconnection between metabolic syndrome and 
neurological disease, which is at the heart of the main aim of this work. 
1.1 The ''plastic brain'': Neural Stem Cells, progenitors and 
precursors  
The adult brain contains a variety of high plasticity cell types, including neural stem cells 
(NSCs) that generate new neurons, as well as neural progenitors, that provide replacement 
glia and neuroprotective factors. However, these terms are often confused. NSCs exhibit two 
main features: (1) they can self-renew indefinitely and (2) they are multipotent for the various 
neuronal and glial cell types. Multipotent progenitors of the adult brain are a type of cell that 
is similar to the neural stem cells. They can self renew but only a limited number of times and 
they can differentiate into at least two different types of cell lineage. On the other hand, 
lineage-specific precursors or progenitors are cells that are still undifferentiated but 
committed to a certain lineage (e.g. neuronal, astroglial or oligodendrocytic) (Emsley et al., 
2005). There is controversy about the biology behind each term and the exact definition as 
the field is still evolving. Thus, often neural stem cells and the different 
progenitors/precursors are all referred as ''precursors''.  
Neural precursor cells are vital for brain tissue health since they are able to: (1) maintain their 
undifferentiated state, and thus, a pool of replacement cells (2) exhibit high mobility (3) resist 
hypoxia and injury (4) proliferate and (5) produce mature neurons and glia. The 
heterogeneity of these cells along with their specialization and differentiation capabilities 
gives great opportunities for medical applications (Emsley et al., 2005; Mitchell et al., 2004). 
Adult neural precursors, with limited differentiation potential towards certain lineages can be 
of great use for the production of certain cell types. This can be of great importance in the 
case of neurodegenerative disease, where depending on the insult different neural cell types 
are affected.  
1.2 Functional adult neurogenesis  
The adult brain exhibits extraordinary stability, which enables the long-term memory storage 
combined with the required amount of plasticity, which is required for adaptation to new 
circumstances as well as for new memory formation. One way that the brain exhibits its 
plasticity as well as its ability to repair itself is with the generation of new cells.  
The existence of NSCs in the adult mammalian brain was inferred in 1962 by Joseph Altman 
who demonstrated the incorporation of tritiated thymidine in adult neurons (Altman, 1962). 
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Later, Kaplan, Gould, and colleagues provided supporting evidence (Eriksson et al., 1998; 
Gage, 2002; Gould et al., 1999; Kaplan and Hinds, 1977; Kaplan, 1981). Goldman and 
Nottebohm reported similar phenomena in the adult songbird brain, demonstrating massive 
seasonal neuronal turnover as male birds develop new songs (Chen et al., 2015). Hockfield 
and McKay identified nestin as a biomarker of fetal NSCs (Hockfield and McKay, 1985), 
while Cattaneo and McKay developed cell culture techniques that allowed the maintenance 
of these cells in vitro (Cattaneo and McKay, 1991). Subsequently, Reynolds and Weiss were 
able to isolate and culture NSCs from the adult mammalian brain, which exhibited 
proliferation capability, as well as the potential of differentiation into neurons and glia after 
treatment with appropriate growth factors in vitro (Sato et al., 2004). These and other studies 
led to efforts aimed at promoting brain repair by either transplanting newly formed neurons 
into the brain, therefore replacing lost cells or by stimulating endogenous NSCs (eNSCs) to 
facilitate their neuroprotective role following brain injury or against degenerative disease 
(Dimou and Gotz, 2014; Hermann et al., 2014).  
1.3 NSCs in conventional and nonconventional regions of 
the adult brain 
Over the last years stem cell research labs have focused mostly on the investigation of the 
cellular source for the de novo generated neurons in the adult mammalian brain. These 
efforts resulted in the discovery of the so called ''stem cell niches''. The two most recognized 
NSC niches of the adult mammalian brain are: (1) the subventricular zone (SVZ) and the sub 
granular zone of the hippocampus (SGZ) (Alvarez-Buylla and Lim, 2004; Luskin, 1993; 
Reynolds and Weiss, 1992). Cells isolated from those areas exhibit self-renewal and 
differentiation potential similar to that of embryonic and fetal derived SCs and they can be 
differentiated into the neurons, astrocytes and oligodentrocytes. Additionally, they express 
traditional NSC markers like the intermediate filament protein nestin (Lendahl et al., 1990). 
More recently, there has been evidence that NSCs reside throughout the brain; they mostly 
maintain their quiescent state and they are in close proximity to the blood vessels as is 
described in Figure 1.1. 
NSCs can be cultured in the form of aggregate cultures (neurospheres) or in the form of a 
monolayer culture. These techniques have been widely used by a variety of labs, which led 
to the establishment of defined culture conditions and protocols. For example a basic 
characteristic of most of the methods is the addition of Epidermal Growth Factor (EGF) or 
basic Fibroblast Growth Factor (bFGF) as a mitogen source, that provide for the expansion 
of multipotent precursors. Neurosphere cultures, which were used traditionally, may be better 
for studying clonal propagation capabilities of an isolated cell type (as it is simple to assess 
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the generation of neurospheres from single cells), however, they comprised a very 
heterogeneous mixture of cell types. In the sphere, depending on their exact location, 
different cells have different accessibility to drugs and proteins added to the culture medium, 
making pharmacological studies more difficult. Likewise, the microenvironment around each 
cell in the sphere may differ, further confounding data interpretation. 
In contrast, monolayer cultures offer a more homogeneous and easy to use system, which 
can be employed for drug screening experiments or signal transduction studies in order to 
study the mechanisms that govern NSC growth and differentiation.  
Androutsellis-Theotokis and Poser presented an established protocol in 2013 about how to 
grow adult NSCs from conventional and non-conventional areas of the brain. This protocol 
enables the generation of adult NSC cultures that can be used for a variety of applications 
from developmental studies to medical application and drug screening (Poser and 
Androutsellis-Theotokis, 2013). This work establishes a technique to further assess the 
differentiation potential of NSCs isolated from the adult rodent brain. 
1.4 Neurodegenerative diseases, cell replacement and 
endogenous NSCs  
Recent findings by various research groups have shown the existence of stem cells in 
various adult tissues. These primary cells are thought to be playing a major role in the 
regeneration of the tissue or the organ they reside in as a response to injury or natural 
turnover of differentiated cells. In the adult mammalian brain, stem cells residing in the 
subventricular zone and the dentate gyrus are part of the mechanism underlying 
neurogenesis for replacement of neurons. However, it is worth mentioning that cell 
replacement is not the only way to respond to an injury. Recent findings show that some 
populations of eNSCs in the CNS may have a neuroprotective function, which could be an 
alternative way to treat brain injury (Kittappa et al., 2012). Thus, activation of eNSCs would 
be another way to treat brain injury. There is great controversy concerning which approach is 
the most effective. However, nowadays we know that the choice between cell replacement 
and endogenous activation of NSCs depends on a variety of factors including the nature of 
the injury and the nature of the tissue. 
Cell replacement strategies through exogenous sources have recently received an enormous 
boost by reprogramming technologies that allow patient-specific cell sources to be converted 
into immature cells (somatic cells into embryonic stem cell-like cells), which can then be 
directed to differentiate towards specific cell fates and then can be grafted into the patient 
(Sanchez Alvarado and Yamanaka, 2014). However, a fundamental hindrance towards 
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achieving functional cell replacement therapy is the complex cytoarchitecture of the CNS. 
Graft-derived neurons need to be precisely placed and they oftentimes need to connect brain 
areas that are centimeters away from each other. In the case of Parkinson's disease (PD) for 
example, dopamine neurons, which extend from the substantia nigra to the striatum, die over 
long periods of time. Following the transplantation approach, injured neurons are replaced in 
one specific area (which usually is the striatum) and the new cells promote dopamine 
production. It has been impossible, however, thus far for those new grafted cells to 
recapitulate the former functional complex neuronal network (Kittappa et al., 2012; 
Nikolakopoulou et al., 2016). Nevertheless, in less complex tissues (e.g. liver) or in cases 
that the stem cell niche is easily accessible the cell replacement approach may be quite 
effective. 
There are several other recent findings that oppose the cell grafting as an effective treatment 
for neurodegenerative disease. There has been evidence from research related to PD and 
amyotrophic lateral sclerosis (ALS) manifesting the fact that neurodegeneration is not 
restricted to certain cell types. When grafted cells were transplanted into the brains of PD 
patients, many acquired the disease themselves (Kordower et al., 2008; Li et al., 2008; 
McKay and Kittappa, 2008; Yamanaka et al., 2008). This supports the idea that cell grafting 
may help with reducing the symptoms of the disease but not in eliminating it. Last but not 
least, a donor-derived brain tumor following neural stem cell transplantation in a boy suffering 
from ataxia telangiectasia was reported in 2009 (Amariglio et al., 2009). This finding was the 
first to suggest that grafted stem/progenitor cells may be involved in gliomagenesis and 
implies the urgent need for further research concerning the safety of such methods.  
In parallel to these efforts, scientists have been exploring the possibility to pharmacologically 
target eNSCs, to increase their number and putative neuroprotective functions. These cells 
are already naturally incorporated into the tissue, within specific microenvironments (the 
neurovascular niche) and by understanding the signals that these cells respond to, it is 
possible to increase their number several fold via direct local injection of a number of soluble 
factors (Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 2009). Two 
evidently contradictory facts about eNSC raise the question of their natural function: (1) 
eNSCs reside in many areas of the adult mammalian brain and they are plentiful and (2) 
Adult Neurogenesis is a rare event (even in the case of injury) and it is confined to certain 
brain areas (the subventricular zone and the subgranular zone of the hippocampus) (Kittappa 
et al., 2012). So, what is the purpose of eNSCs outside the two traditional stem cell niches? 
Recent findings suggest the role of eNSCs in neuroprotection via the production of 
neuroprotective factors such as glial-derived neurotrophic factor (GDNF) and sonic 
hedgehog (SHH) in vivo and in vitro (Androutsellis-Theotokis et al., 2006; Ourednik et al., 
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2002). The neuroprotective function of eNSCs is further supported by the fact that they are 
located close to neurons and blood vessels (Androutsellis-Theotokis et al., 2009) making 
them ideals candidates for trophic support in both the healthy neuronal state and upon 
neuronal injury. The latter phenomenon was observed with the use of novel biomarkers and 
a schematic representing this ''blood vessel-neuron-stem cell association'' is shown in Figure 
1.1.  
eNSCs that differentiate into neurons are also capable of extending axons in significant 
distances throughout the adult brain. Recent experiments have proven their ability to respond 
to growth factors and to differentiate into neurons with long axonal projections that extend in 
large distances and survive for big time periods in areas of the brain that are not traditionally 
neurogenic (Emsley et al., 2005).  
Taken together, these findings suggest that eNSCs are broadly distributed in the adult brain 
and that there are molecular mechanisms that can be used to alter their number, the 
expression of neuroprotective cytokines and that can also be used to control their 
differentiation potential so as to potentially replace injured and lost neurons. 
 
 
Figure 1.1. eNSCs reside in close proximity to the blood vessels and to the neurons. 
Different signals from components of the vascular system (Ang2 and Delta4 from vascular 
endothelial cells, Ang1 from pericytes) regulate the STAT3-Ser/Hes3 Signaling Axis and, 
therefore, eNSCs. 
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1.5 The STAT3-Ser/Hes3 signaling axis in NSCs 
NSCs interpret signaling pathways in their own distinct ways. For example, whereas many 
cell types in the body utilize the JAK/STAT pathway for growth and survival, the same 
pathway leads to the differentiation of NSCs (Bonni et al., 1997; Levy and Darnell, 2002; 
Rajan and McKay, 1998). Specifically, tyrosine phosphorylation of STAT3 is a key 
component of the survival pathway of most cell types, but NSCs avoid this phosphorylation in 
order to avoid differentiating into glia. Instead, NSCs utilize the serine phosphorylation of 
STAT3 for their survival, which is largely redundant for many other cell types (Androutsellis-
Theotokis et al., 2006). Several inputs into STAT3-serine phosphorylation have been 
identified, including a non-canonical branch of Notch signaling (activated by Notch receptor 
ligands such as Delta4 and Jagged1), angiopoietin 2 (a ligand of the Tie2 receptor), basic 
fibroblast growth factor (bFGF), and insulin (Androutsellis-Theotokis et al., 2006; 
Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 2009; Androutsellis-
Theotokis et al., 2010a; Androutsellis-Theotokis et al., 2010b). These treatments lead to the 
transcriptional induction of Hes3, a transcription factor/passive repressor belonging to the 
Hes/Hey family of basic helix-loop-helix genes (Imayoshi and Kageyama, 2014; Lobe, 1997). 
This pathway is opposed by JAK and p38 MAP kinases and, therefore, inhibitors of these 
kinases promote its activation and NSC survival. Hes3 itself mediates many of these 
functions, as adult cultured NSCs show a reduced response to Delta4 and insulin stimulation, 
and to JAK inhibition (Androutsellis-Theotokis et al., 2008). A schematic diagram of the 
STAT3-Ser/Hes3 signaling axis is given in Figure 1.2. 
As an extension of these observations, carcinogenesis is sometimes viewed as the 
manifestation of aberrant regenerative mechanisms. The cells that carry the regenerative 
ability of a tumor, termed cancer stem cells, express genes common to their non-cancerous 
stem cell counterparts (Hanahan and Weinberg, 2011; Poser et al., 2013). In line with this 
notion, putative cancer stem cells from the aggressive brain tumor glioblastoma multiforme 
express Hes3 both in the patient and in culture. Hes3 RNA interference also opposes the 
growth of cultured cancer stem cells from human glioblastoma multiforme biopsies (Park et 
al., 2013). This is a manifestation of how different cell types utilize the same pathway in 
specific ways. A schematic diagram showing the differential use of the STAT3-Ser/Hes3 
signaling axis is shown in Figure 1.3. 
Pharmacological activation of this pathway has powerful consequences as it directly 
promotes the survival of cultured NSCs from many sources. In vivo, the same treatments 
increase the number of putative eNSCs and induce long-lasting neuroprotection in models of 
ischemic stroke and Parkinson’s disease (Androutsellis-Theotokis et al., 2006). One of these 
treatments is the direct injection of insulin into the lateral ventricle of adult rats, suggesting 
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that circulating insulin may also regulate eNSC number and function, and rendering the 
endocrine pancreas a key regulator of the eNSC population in both established neurogenic 
zones, such as the subventricular zone and the subgranular zone of the dentate gyrus of the 
hippocampus, but also in the brain parenchyma (Androutsellis-Theotokis et al., 2008). The 
disease-modifying functions of this pathway may involve, in part, cell replacement but more 
likely, the increased release of neuroprotective factors (Ohta et al., 2012). Hes3, in particular, 
may also be involved in the reprogramming of induced pluripotency cells and adult somatic 
cells to the NSC fate (Cassady et al., 2014; Salewski et al., 2012). 
 
Figure 1.2. The Hes3 signaling pathway. In NSCs STAT3-Tyr phosphorylation leads to 
NSC differentiation, while STAT3-Ser phosphorylation promotes self-renewal. This molecular 
pathway with the STAT3-Ser phosphorylation at its core regulates Hes3 and together they 
form a merging point for several signals including insulin receptor activation (Androutsellis-
Theotokis et al., 2006; Masjkur et al., 2012; Poser et al., 2013) 
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Figure 1.3. Notch signaling in SCs. (A) Simplified diagram showing the canonical and non-
canonical function of the Notch signaling pathway in NSCs. In canonical Notch signaling, the 
cleaved intracellular domain of the Notch receptor translocates to the nucleus where it 
regulates transcription of target genes, including Hes1 and Hes5. A non-canonical branch of 
Notch signaling leads to STAT3-Ser phosphorylation in the absence of detectable STAT3-Tyr 
phosphorylation. This is followed by increased transcription of Hes3. Hes3, in turn, promotes 
growth through poorly understood mechanisms. (B) STA3-Ser/Hes3 signaling promotes 
cancer stem cell (CSC) growth. This exhibits the potential of different cell types to use 
molecular signaling pathways in specific ways (e.g. mature cells like neurons use the 
JAK/STAT pathway leading to STAT3-Tyr phosphorylation for growth as opposed to 
immature cells that the utilize the same pathway to differentiate) (Poser et al., 2013). 
 
Taken together, the regulation of the STAT3-Ser/Hes3 signaling axis is very important in 
regeneration and carcinogenesis. Activation of eNSCs is achievable through a non-canonical 
branch of Notch with STAT3-Ser phosphorylation at its core; multiple treatments that induce 
this modification lead to increased Hes3 expression. For this reason, our lab has studied 
STAT3 and Hes3 in the context of regeneration, cancer and diabetes. 
  
 27 
1.6 Beyond the brain: The STAT3-Ser/Hes3 signaling axis 
operates in plastic cells 
To take full advantage of the therapeutic potential of eNSCs, many aspects of their biology 
need to be further understood, including the molecular mechanisms that regulate their 
number and fate specification, to allow the direction of their fate to appropriate cell types for 
replacement, neuroprotection, or immunomodulation. Throughout this work, we focus on a 
recently identified signaling pathway that regulates the number of NSCs in vitro and in vivo 
(Poser et al., 2013). A major input into the pathway is insulin, providing a new molecular 
mechanism via which the pancreas may regulate aspects of brain function. Thus, we 
hypothesized that the STAT3-Ser/Hes3 signaling axis may be relevant to other parts of the 
neuroendocrine system. Indeed, recent work shows the operation of this pathway in the 
pancreas, the adrenal gland and the hypothalamus (Masjkur et al., 2014a; Masjkur et al., 
2014b; Nikolakopoulou et al., 2016), suggesting that it deserves further study with relevance 
to metabolism and the neuroendocrine system.  
1.6.1 STAT3-Ser/Hes3 Signaling Axis in the pancreatic islet 
It appears highly likely, then, that the endocrine pancreas can regulate aspects of brain 
functions, such as neuroprotection and regeneration, via the release of insulin and its actions 
on endogenous NSCs. Molecular mechanisms that regulate insulin production/release and 
pancreatic islet beta cell properties may thus be directly relevant to brain function (Ziegler et 
al., 2015). Remarkably, the same signaling pathway also regulates key functions of 
pancreatic islets, as well as their resistance to damage. These observations suggest that the 
STAT3-Ser/Hes3 Signaling Axis in the pancreas regulates the same signaling pathway in 
eNSCs and with it, the function of both of these cell types (Nikolakopoulou et al., 2016). 
Specifically, Hes3 is expressed in pancreatic islets and Hes3 null mice exhibit more 
pronounced damage to the pancreatic islet beta cell population when treated with the toxin 
streptozotocin (STZ), relative to wild type controls (Masjkur et al., 2014a), resulting in a 
greater loss of beta cells and an earlier diabetic phenotype, as assessed by blood glucose 
levels. Following STZ-induced damage, Hes3 promoter activity (in this study the activity of 
only one of the two promoters, Hes3a, was assessed) is elevated, suggesting an 
involvement in pancreatic islet regeneration (Figure 1.4). 
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1.6.2 STAT3-Ser/Hes3 Signaling Axis in the adrenal cortex and 
medulla 
We recently reported Hes3 expression in the bovine adrenal medulla and in cultures of 
chromaffin progenitor cells from this tissue (Masjkur et al., 2014c). Using a reporter mouse 
strain where the Hes3 gene has been replaced by the lacZ gene under the control of the 
Hes3a promoter (one of the two known promoters of Hes3) (Hirata et al., 2000), we also 
showed the expression of Hes3 in the mouse medulla, corroborating the bovine data (Fig. 1). 
In addition, we reported Hes3a promoter activity in the adrenal cortex. In the cortex, Hes3 
expression was most prominent in the zona glomerulosa, where sonic hedgehog (Shh) – 
expressing progenitor cells reside (Laufer et al., 2012). Because in NSCs, Hes3 is a positive 
regulator of Shh expression (Androutsellis-Theotokis et al., 2006), this observation raises the 
question of whether Hes3 is expressed in adrenocortical progenitors and whether it functions 
to induce Shh expression. Copper chelation by a cuprizone-rich diet induces massive 
upregulation of Hes3a promoter activity further suggesting that different insult paradigms 
should be investigated to unveil roles of the STAT3-Ser/Hes3 Signaling Axis (Nikolakopoulou 
et al., 2016) (Figure 1.4). 
1.6.3 STAT3-Ser/Hes3 Signaling Axis in tanycytes of the 
hypothalamus? 
The STAT3-Ser/Hes3 Signaling Axis regulates pancreatic beta cells as well as neural and 
neuroendocrine stem cells and progenitor cells in the adult brain and adrenal gland. Given 
this broad range of cells that utilize the pathway, it is reasonable to speculate that 
hypothalamic tanycytes may also be subject to regulation by this pathway. Indeed, tanycytes 
of the median eminence express Hes3 (Figure 1.4). It remains to be determined how this 
pathway may affect the stem/progenitor cell properties of tanycytes and, as a consequence, 
metabolic regulatory functions of the hypothalamus. 
The question of how the stem cell/progenitor properties of tanycytes come into play in 
hypothalamic function is still under intense investigation. Tanycytes may be non-terminally 
specified immature cells tasked with the ability for metabolic sensing (a complex biochemical 
function) and, at the same time, the capacity to contribute to tissue remodeling by generating 
new neurons. In this way, tanycytes may be able to dynamically contribute to tissue plasticity, 
in response to dietary and other changes (Bolborea and Dale, 2013) . 
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1.6.4 STAT3-Ser/Hes3 Signaling: A new molecular component of the 
neuroendocrine system? 
Hes3 is expressed in pancreatic islet cells where it regulates insulin release (at least in vitro) 
and regenerative responses (in vivo). Insulin (direct injections into the lateral ventricle) 
regulates the number of endogenous neural progenitor cells in the adult brain. Hes3-
expressing cells in the adult brain are found in a number of areas, including the SVZ, 
cerebral cortex, hippocampus, and hypothalamus (Figure 1.4 green arrows and red box). In 
the hypothalamus, Hes3+ cells are found in the median eminence where a fraction of them 
co-localizes with vimentin-expressing β2 tanycytes. Hes3 expression in these cells raises the 
question of possible roles of Hes3 in the neuroendocrine system, for example, through the 
regulation of adrenal function via the HPA Axis. The adrenal gland also contains Hes3-
expressing cells. In the adult mouse adrenal medulla it co-localizes with a subpopulation of 
nestin positive cells (nestin-GFP). The magnification in the right side of the panel shows a 
perinuclear localization of Hes3 in nestin-GFP positive cells (yellow arrow), whereas cells 
negative for nestin-GFP displayed a nuclear localization of Hes3 (blue arrow; Scale 50 µm). 
Hes3+ cells in the adrenal medulla exhibit a scattered distribution and may represent 
adrenomedullary chromaffin progenitors, as suggested by in vitro studies showing the 
expression of Hes3 in isolated cultured progenitors. In the adrenal cortex, Hes3+ cells are 
located in the general area where progenitor cells are also thought to reside. Copper 
chelation by a cuprizone-containing diet induces massive activation of Hes3a promoter 
activity in the adrenal (Figure 1.4). 
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Figure 1.4. The STAT3-Ser/Hes3 signaling axis in the neuroendocrine system. Hes3 is 
expressed in the pancreatic islet, in the progenitor cells of the adrenal cortex and medulla 
and in the tanycytes of the hypothalamus. A detailed description is provided in the text 
(Nikolakopoulou et al., 2016). 
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1.7 Metabolic syndrome and neurological disease 
Recent evidence manifests a clear connection between the occurrence and progression of 
neurodegenerative disease and metabolic dysfunction, manifesting how impaired metabolism 
may intensify neurological symptoms (Farooqui et al., 2012; Procaccini et al., 2016). Here, 
the evidence relevant to Alzheimer's disease, Parkinson's disease and Multiple Sclerosis is 
reviewed.  
1.7.1 Metabolic dysfunction and Alzheimer's disease 
Alzheimer's disease (AD) is the most recognized form of dementia and it typically begins with 
subtle memory loss. With age, cognitive decline and memory loss become severe resulting in 
poor quality of life and eventually death (Lee et al., 2001). Recent findings support the idea of 
a link between impaired metabolism and AD progression. Specifically it was shown that: (1) 
High Body Mass Index (BMI) and Type 2 diabetes increase the risk for AD, (2) Leptin, insulin 
and IGF-1 resistance correlate with AD, (3) Insulin signaling is altered in AD, (4) Treatment 
with diabetes treatments like several agonists of insulin, IGF-1 and GLP-1 shows beneficial 
effects on AD, (5) Leptin administration decreases serum levels of Aβ and improves cognitive 
performance, (6) Ghrelin has neuroprotective function and reduces reactive oxygen species 
(ROS) production and cytochrome c release and (7) Hyper/Hypo-activation of the mTOR 
pathway is a risk for AD and associates with reduction in autophagy (Procaccini et al., 2016). 
1.7.2 Metabolic dysfunction and Parkinson's disease 
Parkinson's disease (PD) is one of the most common neurodegenerative diseases, which 
mainly affects the motor system and has as main outcome the '' Parkinsonism'', a syndrome 
characterized by intense disabilities (Rocha et al.). Recent findings support the idea of a link 
between impaired metabolism and the progression of PD. Those are: (1) Insulin/IGF-1 
resistance and Type 2 diabetes worsen PD (2) The reduction of insulin relates to α-synuclein 
aggregation (3) GLP-1 agonists exhibit beneficial effects on PD (4) High or low IGF-1 levels 
associate with negative effects on PD (4) Leptin and ghrelin play a role in PD development 
(5) Impaired mTOR signaling is associated with PD and (6) Prolonged mTOR activity can 
lead to dyskinesia in PD patients (Procaccini et al., 2016). 
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1.7.3 Metabolic dysfunction and Multiple Sclerosis 
Multiple Sclerosis (MS) is the most common chronic autoimmune inflammatory degenerating 
disease of the CNS, characterized by confined areas of inflammation, demyelination, axonal 
loss, and gliosis in both the brain and the spinal cord. In long term, MS leads to severe 
neurological symptoms (Milo and Miller, 2014). For many years, MS was considered as a 
strictly autoimmune disease; nevertheless, with the recognition that the neurological deficits 
come as a result of neurodegeneration the whole perception changed. Specifically, while the 
primary pathological cause of MS is the immune mediated destruction of myelin in the CNS, 
it is now understood that the neurological disability observed in MS patient is a result of the 
progressive axonal loss (Stadelmann et al., 2008; Trapp and Nave, 2008). 
As described above for the case of AD and PD, recent evidence has suggested a direct 
crosstalk between metabolic alterations and the neurodegeneration observed in MS. 
Specifically: (1) Obesity is a risk factor for MS; (2) Leptin-deficient ob/ob mice are resistant to 
experimental autoimmune encephalomyelitis (EAE) (the most widely used model of MS); (3) 
Low calorie intake increases EAE lifespan; (4) IGF1 prevents the progression of MS; (4) 
Hyper activation of mTOR signaling relates to defective mechanisms of autophagy; (5) Leptin 
acts as neurotrophic factor and (6) Ghrelin decreases the severity of the EAE symptoms 
(Procaccini et al., 2016). 
 
1.7.4 Metabolism and neurodegenerative disease: Are they 
connected? 
Taken together, recent findings of the scientific community suggest a strong connection 
between metabolism and neurodegeneration. According to this scenario, hormones like 
insulin, leptin and ghrelin may have a far more important role than as feeding and appetite 
regulators. They exhibit neuroprotective functions and further research in this field could 
result in better outcomes for neurodegenerative disease and potential novel drug discovery 
possibilities.  
During the last years a connection between metabolic disorders and neurodegeneration has 
been established. However, the mechanisms underlying the pathogenesis of the 
neurodegeneration due to alterations in metabolism remain largely unknown. Therefore, it is 
crucial to develop tools that detect tissue alterations due to metabolic disorders. Such an 
approach may lead to better therapeutic strategy and prevention. 
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1.8 Main Aim – Hypothesis 
STAT3-Ser/Hes3 signaling regulates various plastic cell populations in multiple organs of the 
endocrine/neuroendocrine system.  
Insulin is a master regulator of the pathway and, as a result, we hypothesized that the 
STAT3-Ser/Hes3 Signaling may be involved in tissue problems that result from metabolic 
dysfunction. Metabolic syndrome often results in diabetes (Type I, Type II) and insulin 
resistance, suggesting that eNSCs may be affected by the condition. There is evidence that 
obesity induces inflammatory reactions in the hypothalamus, leading to NSC loss (Livesey, 
2012). However, it is not clear if damage to NSCs is also directly linked to insulin signaling 
disruption. Recent findings suggest an interconnection between metabolic disorders and 
neurological disease. Thus, it is crucial to maintain homeostasis of the eNSCs of the brain in 
such conditions. It is therefore mandatory to develop tools and biomarkers capable of 
detecting the altered eNSC state in the brain.  
The main aim of my study is to investigate whether the STAT3-Ser/Hes3 signaling axis and, 
specifically, Hes3 expression can be utilized as a tool to assess the brain state in metabolic 
syndrome and aging. Thus, this work has three main objectives: (a) to confirm that Hes3 is 
expressed in specific mouse brain areas (b) to investigate if eNSCs are affected by metabolic 
syndrome and aging with the use of Hes3 as a biomarker and (c) to assess the importance 
and the functionality of the Hes3 gene in metabolic syndrome. 
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2 Materials and Methods 
2.1 Animal experiments 
2.1.1 Animal use authorization 
Adult C57Bl/6J mice or Hes3 null mice in the C57Bl/6J background were used throughout the 
experiments. The Hes3 null mouse line was kindly provided by R. Kageyama (Hirata et al., 
2001). 6 week-old male mice were either obtained from Janvier or bred in MPI-CBG or the 
Medical Faculty’s animal house in Dresden, Germany. Mice were used according to our 
experimental needs and in accordance with the approved guidelines from the 
Landesdirektion Sachsen. Mice were kept under normal conditions [Food (Normal diet unless 
stated differently) and water ab libitum, 12:12h light-dark cycle, temperature controlled room 
(20-22°C)]. Bedding was changed in the cages once per week. At the GMC mice are housed 
according to the GMC housing conditions and German laws. All tests performed at the GMC 
were approved by the responsible authority of the district government of Upper Bavaria, 
Germany.  
2.1.2 Genotyping  
Genotyping of the mice for the experiments among WT and Hes3 null mice was performed 
either in house or in the MPI-CBG facility using the primers and the following protocols:  
Hes3 Genotyping 
Hes3 +: FW 5' GGCGGGCTGCACGCTTTAATGGGACACATG-3     
Hes3 KO (-): REV 5'-ATTACGCCAGCTGGCGAAAGGGGGATGTGC-3  
Hes3 WT (-):  REV 5'-CACTATGTCTGCTTGCCAAGTCCTGGCTGC-3'  
The Reverse Transcriptase PCR (PCR) reaction has three primers and not two. It is 
designed this way to allow us to identify heterozygotes from homozygotes in a single 
 35 
reaction. Homozygotes can be Hes3+, Hes3+ or they can be LacZ+, LacZ+. The Hes3+ band 
is approximately 441bp and the band from the LacZ is around 838bp. So, the homozygote 
Hes3 will give only one band size 441bp, the homozygote for LacZ will give only one band 
838bp and the heterozygote will give both bands (441bp and 838bp). The DNA region that 
we wanted to amplify is GC rich and therefore we added betaine enhancer solution (Sigma, 
B0300). PCR reactions were performed using 5-50ngr of genomic DNA, 10x buffer, 2.5mM 
dNTPs, 10x PCR betaine, 10 µM primer Hes3+, 10 µM primer Hes3 WT- , 10 µM primer 
Hes3 KO, Taq DNA polymerase (5U/µl) and ddH2O to the desired final volume. The PCR 
reactions were performed with the following protocol: 
Step Temperature (°C) Time # Cycles 
Initial Denaturation 95 2 min 1 
Denaturation 95 30 sec  
35 Annealing 63 1 min 
Extension 72 2 min + 5sec/cycle 
Final extension 72 5 min 1 
LacZ detection was used as an extra positive control. The primers that we used detect only 
the presence of the LacZ gene and they are the following: LacZ FW: 5'-
CTGCGATGTCGGTTTCCG-3 LacZ RV: 5'-GGATGGTTCGGATAATGCG-3'. PCR reaction 
for LacZ primer pair is: 
Step Temperature (°C) Time # Cycles 
Initial Denaturation 94 5 min 1 
Denaturation 94 45 sec  
30 Annealing 63 45 min 
Extension 72 1 min 30sec 
Final extension 72 10 min 1 
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2.1.3 In vivo models 
2.1.3.1 Aging  
For the aging experiments mice were divided into several groups and kept under normal 
conditions until certain time points. We investigated aging effects on Hes3 expression on 
young mice (4 months old) versus older mice (8 months and 10 months old). 
2.1.3.2 Diabetes mouse models 
Prior to the experiments all mice were subjected to a one to two week acclimatization period 
to the housing conditions. Type I diabetes-Single High Dose STZ: 8 week-old mice were 
injected intraperitoneally [phosphate-buffered saline (PBS) vehicle control or STZ (180 
mg/kg, Sigma Aldrich, S0130)] and were euthanized 8 weeks later.  
Type II diabetes-HFD: 8 week old mice were fed Normal Diet (ND, 10% kcal % fat, D12450B, 
OpenSource Diets – Research Diets) or High Fat Diet (HFD, 60% kcal % fat, D12450B, 
OpenSource Diets – Research Diets) and euthanized after ~10 weeks ("Short Feeding"), or 
~30 weeks ("Long Feeding").  
2.1.3.3 Metformin administration 
24 mice were divided into two groups, one served as control group and one as experimental 
group. Metformin was administered in the drinking water (2g/l, Sigma, D-150959) starting at 
the eight weeks of age. Water was changed 2 times per week and mice were euthanized 8 
weeks later. 
2.1.4 In vivo metabolic Analyses 
In all the in vivo experiments body weight (BW) was measured weekly at the same time of 
the day.  
Intraperitoneal glucose tolerance test (ipGTT): Mice were used for the glucose tolerance test 
after a 16-18 hours-lasting overnight food-withdrawal. In the beginning of the test, the body 
weight of mice was determined. For the determination of the fasting blood glucose level, the 
tip of the tail was scored using a sterilized scalpel blade and a small drop of blood was 
analyzed with the Accu-Chek Aviva glucose analyzer (Roche/Mannheim). Thereafter mice 
were injected intraperitoneally with 2 g of glucose/kg body weight using a 20 % glucose 
solution, a 25-gauge needle, and a 1-ml syringe. 15, 30, 60 and 120 minutes after glucose 
injection, additional blood samples (one drop each) were collected and used to determine 
blood glucose levels as described before. After the experiment was finished, mice were 
placed in a cage with plentiful supply of water and food.  
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Intraperitoneal insulin tolerance test (ipITT): Prior to the ipITT mice were fasted for 6h. We 
then followed the procedure described above for the ipGTT. After fasting, BW and glucose 
levels were determined (fasting values, time point 0) and then the mice were injected with 
insulin (Lilly, Bad Homburg, Germany) (0.75U/kg of body weight). Blood glucose levels were 
determined 15, 30, 60 and 120 minutes post injection. After the experiment was finished, 
mice were placed in a cage with plentiful supply of water and food. 
Fasting BW, Fasting Blood Insulin, and Fasting Blood Glucose levels: Prior to euthanization 
mice were fasted overnight. The next morning and prior to euthanization, fasting values of 
BW and glucose levels were determined. Mice were euthanized and blood samples were 
collected for serum insulin determination. Serum insulin concentration was determined with 
an ultra-sensitive mouse insulin enzyme-linked immunosorbent assay (ELISA) kit (90080, 
Crystal Chem) and according to the manufacturer’s instructions.   
2.1.5 Nociception 
Pain is the perception of an aversive or unpleasant sensation that originates from a specific 
region of the body. The highly subjective nature of pain is one of the factors that make it 
difficult to define and to treat clinically. Pain is more than a conspicuous sensory experience 
that warns of danger. 
Nociceptors are activated by tissue injury but also by mechanical, thermal, or chemical 
stimuli. Harmful stimuli applied to the skin or to subcutaneous tissue, activate nociceptors, 
the peripheral endings of primary sensory neurons whose cell bodies are located in the 
dorsal root or in the trigeminal ganglia. 
The hot plate test 
 The hot plate test was used in order to assess the responsiveness of the somatosensory 
system of the Hes3 null mice to thermal pain (nociceptive pain). The mice were placed on a 
metal surface maintained at 52 ± 0.2 C (Hot plate system was made by TSE GMBH, 
Germany. Locomotion of the mouse on the hot plate was constrained by 20 cm high 
Plexiglas wall to a circular area with a diameter of 28 cm. Mice remained on the plate until 
they performed one of three behaviors regarded as indicative of nociception: hind paw lick 
(h.p. licking), hind paw shake/flutter (h.p. shaking) or jumping. 
We evaluated only hind paw but not the front paw responses, because fore paw licking and 
lifting are components of normal grooming behavior. Each mouse was tested only once since 
repeated testing leads to profound changes in response latencies. The latency was recorded 
to the nearest 0.1 s. To avoid tissue injury 30 s cut-off time was used. The data values are 
given in seconds. 
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2.1.6 Histology 
2.1.6.1 Organ isolation and Tissue Preparation 
Brains were dissected, fixed overnight and cryoprotected in 30% sucrose solution phosphate 
buffered saline at 4°C until sinking. Brains were then embedded in Tissue-Tek optimal cutting 
temperature (O.C.T.) compound (VWR 25608-930). We identified the mouse brain areas that 
we were interested in with the use the Mouse Brain Atlas (Franklin and Paxinos, 2008). 
Tissue slices were prepared in the cryostat and mounted on glass slides. Slides were either 
processed directly of frozen (minus 80 degrees) until further use.  
2.1.6.2 Immunofluorescence  
For immunofluorescence (IF) staining the following protocol was followed. Slides were 
allowed to dry in room temperature (RT) for 10-15 minutes prior to staining. Then, they were 
washed with PBS (1 fast, 2 x 5min washes) while shaking. Slides were then incubated for 1h 
in permeabilization solution (0.3% Triton X in PBS). Washes with PBS followed (3x10min) 
and then slides were incubated for 1h in blocking solution [5% BSA-0.1% Tween-20 in PBS 
(PBS-T)]. Primary antibodies were diluted in blocking solution and overnight incubation in RT 
followed. The next day, sections were washed thoroughly (3x15min with PBS-T, RT) and 
then secondary antibody incubation (diluted in blocking solution) for 1h in RT followed. Nuclei 
were stained with 4′, 6-Diamidin-2-phenylindol (DAPI) diluted in PBS (1:10000). 2 last 
washes with PBS followed and slides were mounted (Aqua-Poly/Mount, 18606, 
Polysciences). Slides were directly imaged or stored at 4°C for further processing. A 
complete list of the antibodies and the respective dilutions is provided in the form of a table in 
the end of the section 1.1.6. 
2.1.6.3 Whole mount brain staining for β-Galactosidase using X-gal 
Whole mount X-gal staining: Brains were dissected and fixed in 2% PFA. They were then 
washed 3 times with washing solution [0.02% Nonidet P40 (NP40) in PB (0.1M phosphate 
buffer pH7.2); (3x20mins, RT)]. 1mgr/ml 5-bromo-4-chloro-3-indolyl-beta-D-galacto-
pyranoside (X-Gal, ThermoFisher, R0404) was diluted in working stain solution (5mM 
K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM MgCl2 and 5mM EGTA in PB), and brains were stained in 
the dark overnight in RT or 37°C depending on the strength of the staining. Washes with cold 
PBS followed and images of the brains were acquired with a standard camera. (β-
Galactosidase detection in certain brain areas was performed with antibody staining as 
described above). 
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2.1.6.4 Imaging and Analysis  
Images were acquired with a Zeiss Axiovison Apotome fluorescent microscope or a Zeiss 
LSM780 confocal system. Image analysis was performed using the Fiji software (Schindelin 
et al., 2012).  
Primary Antibodies         
Antibody Company Catalogue # Host species Dilution 
Hes3 Santa Cruz sc-25393 rabbit 1/100 
Hes3 (B-6) Santa Cruz sc-398654 mouse 1/100 
Hes3 (B-12) Santa Cruz sc-55587 mouse 1/100 
LacZ MP Biomedicals 8559762 rabbit 1/500 
Vimentin Abcam ab24525 chicken 1/2000 
SecondaryAntibodies 
Type Company Catalogue # Host species Dilution 
a-rabbit IgG 594 Jackson ImmunoResearch  711-515-152  donkey  1/500 
a-mouse IgG 488  Jackson ImmunoResearch  715-485-151  donkey  1/500 
a-chicken IgY 488  Jackson ImmunoResearch  703-546-155 goat 1/500 
2.1.7 PCR and Real-Time quantitative PCR (qPCR) 
2.1.7.1  Tissue Collection and RNA Isolation  
Brain tissues were dissected on ice. Depending on the experimental plan brain without 
cerebellum and olfactory bulb (indicated as BRAIN), brain without cerebellum, olfactory bulb 
and hypothalamus (indicated as Remaining Brain ‘’RB’’), hypothalamus (HPT) and 
cerebellum (CBL) were dissected. RB was split into two hemispheres and one was directly 
processed for RNA extraction. CBL was also divided in two parts and the same procedure 
was followed. Full HPT was used for the RNA extraction. Total RNA was isolated with the 
High Pure RNA isolation kit (Roche, 11828665001) and 1 µg of total RNA per sample was 
reverse transcribed using Promega M-MLV reverse transcriptase (Promega, M170B).  
 40 
2.1.7.2  PCR and qPCR experiments 
PCR experiments were performed with DreamTaq Green DNA Polymerase (EP0712, 
ThermoScientific and the respective protocol) consisting of 3-5 ul cDNA (always synthesized 
from 1µgr RNA), 0.2uM of each primer, 0.2uM dNTPs and 0.75U Taq Polymerase per 
reaction.with addition of betaine (5M, Sigma, B0300) and ddH2O to a final 30ul reaction 
volume. qPCR experiments were performed with SsoFast EvaGreen Supermix (172-5201, 
Biorad)  in a CFX384 Real time PCR Detection System. Relative gene expression was 
evaluated with the ΔΔCt method upon normalization to hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). The primer sets and reaction protocols are listed below. 
Primer Sets used for PCR and qPCR experiments: 
Gene		 Seq5’—>3’	FW	 Seq5’—>3’	REV	 Method		
mHes1		 AAGATAGCTCCCGGCATTCCAAGC	 AGCGCGGCGGTCATCTGC	 PCR;	qPCR	
mHes3	 AAAGCTGGAGAAGGCCGATA	 TCCTTGCCTACGTCTCACCA	 PCR	
mHes3a	 GTGATCTCCAAGCCTCTGATGGAGAA	 CAGCTTTCGTTTCCGTATCTGATGTGA	 PCR;	qPCR	
mHes3b	 CCAGCAGCTTCCGAAAGATCTCCA	 TCTCCAGCTTTCGTTTCCGTATCTGA	 PCR;	qPCR	
mHes5	 CAACAGCAGCATAGAGCAGC	 AGGCTTTGCTGTGTTTCAGG	 PCR;	qPCR	
mHes6	 GGTGCAGGCCAAGCTAGAG	 TGAAAGCTGCTACCCTCACG	 PCR;	qPCR	
mHes7	 CCCAAGATGCTGAAGCCGTTGGT	 AGCTTCGGGTTCCGGAGGTTCT	 PCR;	qPCR	
mHey1	 AGGCATCATCGAGAAGCGCC	 AGCTTAGCAGATCCCTGCTTCTCA	 PCR;	qPCR	
mHey2	 TGAGAAGACTAGTGCCAACAGC	 TGGGCATCAAAGTAGCCTTTA	 PCR;	qPCR	
mHeyL	 CAGCCCTTCGCAGATGCAA	 CCAATCGTCGCAATTCAGAAAG	 PCR;	qPCR	
mHPRT		 AAGCTTGCTGGTGAAAAGGA	 TTGCGCTCATCTTAGGCTTT		 PCR;	qPCR	
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PCR Protocol steps: 
Step Temperature (°C) Time # Cycles 
Initial Denaturation 95 10 min 1 
Denaturation 95 4 min 
35 Annealing 60 30s 
Extension 72 1 min 
Final extension 72 10 min 1 
qPCR Protocol steps: 
Cycling Step Temp (°C) Time  # Cycles 
Enzyme activation 95 1 min 1 
Denaturation 95 5 sec 
40 
Annealing/Extension 60 15 sec  
Melt Curve 65-95°C (in 0.5 °C increment) 5 sec/step 1 
2.1.8 Western Blot 
2.1.8.1 Protein Isolation and Western Blot  
Mice were euthanized and brain tissues were dissected on ice. Whole brains or brain tissue 
parts (as indicated) were dissected and tissue was lysed in 300-500µl (depending on the 
tissue part) lysis buffer using an IKA® T10 basic ULTRA-TURRRAX® mechanical tissue 
homogenizer. Lysis buffer contained RIPA lysis buffer with addition of 7x cOmplete, Mini 
protease inhibitor cocktail (Roche, 11836153001) and 10x PhosSTOP phosphatase inhibitor 
cocktail (Roche, 04906845001). Tissue was either processed directly for WB experiments or 
stored in -80°C for further use. Protein concentration was determined in Qubit® 2.0 
Fluorometer (Invitrogen) with the Qubit® Protein Assay Kit (Q33211, Life Technologies) 
according to the manufacturer’s instructions.  Protein was loaded equally (30-60µgr) on each 
lane of a 4%-12% gradient Nu-PAGE Mini Tris-Base gel and run in an XCell Sure-Lock® 
Mini-Cell System (Invitrogen) with NuPAGE® MOPS SDS Running Buffer (Invitrogen 
NP0001). The XCell IITM Blot Module (Invitrogen) was used for the transfer of proteins to 
nitrocellulose membrane. Throughout the procedure the instructions of the manufacturer 
were followed accompanying the WB system. The successful protein transfer was verified 
with ponceau staining (P7170, Sigma). Membranes were washed 3 times with TBS-T and 
blocked for 1h in blocking buffer in RT. Primary antibody was diluted in blocking buffer and 
with no washing step, overnight incubation of the membranes in the primary antibody 
solution followed (4°C, shaking). The next day, the membranes were washed thoroughly 
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(3x15mins in TBS-T). Peroxidase conjugated secondary antibodies were diluted in 5% fat-
free milk in TBS-T and then incubation with the secondary antibody followed (1h, RT, 
shaking). Membranes were washed again with TBS-T (3x15mins, RT). Lastly, membranes 
were incubated in SuperSignal™ West Pico or Femto Chemiluminescent Substrate (34080 
or 34095, Invitrogen) and imaging followed with a LAS4000 system. A complete list of the 
antibodies and the respective dilutions is provided below. 
Primary Antibodies 
Antibody Company Catalogue # Host species Dilution 
Hes3 Santa Cruz sc-25393 rabbit 1/100 
Hes3 (B-6) Santa Cruz sc-398654 mouse 1/100 
Hes3 (B-12) Santa Cruz sc-55587 mouse 1/100 
STAT3 (pan) Santa Cruz sc-293151  mouse  1/200 
Phospho-STAT3 (Ser 727) Cell Signaling  9134 rabbit  1/1000 
Phospho-STAT3 (Tyr 705) Cell Signaling  9145 rabbit  1/2000 
AKT (pan) Cell Signaling  4691 rabbit  1/1000 
Phospho-AKT (Ser 473) Cell Signaling  4060 rabbit  1/2000 
GAPDH Abcam  ab8245 mouse  1/10000 
Secondary Antibodies  
Type Company Catalogue # Dilution 
a-mouse IgG HRP-conj Jackson ImmunoResearch  115-035-003 1/2500 
a-rabbit IgG HRP-conj R&D systems HAF008 1/2500 
2.2 Mouse phenotyping 
Comprehensive phenotypical characterization of Hes3 null mice was done in collaboration 
with the German Mouse Clinic (GMC), Munich, Germany (Gailus-Durner et al., 2005). 
Beginning with the age of 9 weeks, a total of 64 mice (16 males, 16 females, 16 control 
males and 16 control females) were subjected to various non-invasive tests including 
dysmorphology, cardiovascular health, energy metabolism, clinical chemistry, eye, behavior, 
neurology, nociception, immunology, allergy, and pathology. Tests were conducted using the 
protocols described before (Fuchs et al., 2011) and referenced at https://www.mouseclinic.de 
(Click on "VIEW RESULTS OF MUTANT LINES" or "phenomap" and search for project 
"Hes3_KO").  
In a second cohort (11 males, 11 females, 11 control males and 11 control females) we 
conducted a 24-weeks high fat challenge feeding a purified diet [E15741-347 (D12492 mod.) 
Ssniff Spezialdiäten GmbH, Soest, Germany, containing 60 energy-% from beef tallow]. Mice 
were subjected to the following tests beginning at the age of 12-13 weeks: Body composition 
analysis (qNMR, Minispec LF 50, Bruker, Ettlingen, Germany), 21 hours indirect calorimetry 
(Phenomaster, TSE Systems Gmbh, Bad Homburg, Germany), rectal body temperature, 
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body surface temperature (thermosensor: Almemo ZA 9040, data logger: Almemo 2290-8, 
Ahlborn, Holzkirchen, Germany), and ipGTT after overnight food deprivation. 
2.3 Neural stem cell cultures  
2.3.1 Preparation – Coatings 
Fetal Neural Stem Cells (fNSCs) were grown throughout the experiments on Poly-L-ornithine 
[PLO (Sigma, P3655)] – bovine Fibronectin [bFib (R&D Systems, 1030-FN)] coated flasks, 
dishes and plates depending on our experimental needs. Plastic bottom dishes: PLO was 
used at concentration of 75µg/ml in ddH2O (5x) and bFib at a concentration of 1µg/ml in 
PBS. Glass bottom dishes: PLO was used at concentration of 495µg/ml in ddH2O (5x) and 
bFib at a concentration of 10µg/ml in PBS. Culture dishes were coated with PLO 2 days 
before plating the cells and for at least 24 hours. Next day dishes were washed with PBS 
(1fast, 2x5min) and then they were coated with bFib for at least 24 hours as well. Before 
plating the cells the culture dishes were washed twice with PBS (1fast, 2x5min). 
2.3.2 Cell Isolation and Cell Culture  
fNSCs were dissected and cultured from mouse embryos at embryonic day 13.5 (E13.5) 
following previously described and established protocols (Johe et al., 1996). Cells were 
grown in serum-free N2 medium [DMEM-F12 (Sigma Aldrich, D8062), 100 µg/mL Apo-
Transferrin (Sigma Aldrich, T2036), 10 mg/ml Insulin (I9278, Sigma Aldrich) 20 nM 
Progesterone (Sigma Aldrich, P8783), 100 µM Putrescine (Sigma Aldrich, P5780) and 30 nM 
Selenite (Sigma Aldrich, S5261), 100 µg/mL Pen-Strep (Life Technologies, 15140122)]. For 
NSC maintenance basic fibroblast growth factor [bFGF (233-FB-01M, R&D Systems)] was 
added to the cells at a concentration of 20ng/ml daily as described before (Poser and 
Androutsellis-Theotokis, 2013). After dissection cells were plated and they were grown for 3-
4 days (bFGF every day, media change every 2 days). After 4-5 days in culture cells were 
passaged to new precoated dishes. At this point the culture is relatively homogeneous and it 
is mostly comprised of Nestin (a marker of NSCs (Hockfield and McKay, 1985)) positive 
multipotent precursors. To induce differentiation to neurons and glia the N2+bFGF medium 
was replaced with N2-bFGF. Cells were fed for time periods above 5 days and medium was 
changed every 2 days. 
2.3.3 Pharmacological Manipulation (Metformin – Exendin-4)  
Dose dependence experiments – Cell Number: Cells were seeded at 10,000 cells per well 
in a 12 well plate and treated with different concentrations of metformin (Sigma, D-150959) 
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or exendin-4 [Ex-4 (Biotrend, BP0111)] beginning 24 hours after plating. Cells were fixed 
after 72h with 4% PFA for 20 minutes and nuclei were stained with 4',6-Diamidino-2 
Phenylindole (DAPI). 
Cell Proliferation: fNSCs proliferation was determined after 72h by incubating the cells with 
10 µM 5-ethynyl-2´-deoxyuridine (EdU) for 5h and followed by visualization using the Click-IT 
EdU Alexa Fluor 594 Imaging Kit (Invitrogen C10339) following the manufacturer’s 
instructions. Five images (using a 20x objective) from each well were acquired (3 wells per 
plate) with a standard Zeiss structured illumination microscope (Zeiss – Axio Observer Z1, 
inverted) and cells were counted using the Fiji software. The same procedure was followed 
for both cell number and proliferation experiments. 
PCR/qPCR: For the time-course experiments cells were seeded at 500,000 cells per T25 
flask and treatments (0 or 500 µM metformin and 0 or 200nM Ex-4) were added 24hours 
after plating. Cells were collected at 6, 24, 48, and 72h and processed directly for PCR/qPCR 
experiments. Cell culture medium (including bFGF and the respective treatment was 
changed every 24hours. 
Western Blot: Cells were washed quickly on ice with cold PBS. 30 µl of lysis buffer was 
added to the cells and they were detached using a cell scrubber. Samples were either 
processed directly for WB experiments or stored in -80°C for further use. Western blot 
experiments were performed as described above (see section 2.1.8.1.)  
2.4 Heat maps 
Heat maps were generated in Morpheus https://software.broadinstitute.org/morpheus/. 
2.5 Statistical analyses 
Data are expressed as means ± SEM. Statistical analyses were performed in Graphpad 
Prism (GraphPad Software, Inc., San Diego, CA). The Student's t test, a Mann- Whitney U 
test, or one-way ANOVA were used and significance was set at p < 0.05 (denoted as an 
asterisk in the figures). A detailed account of the statistical methods used in the phenotypic 
analysis of the Hes3 null mice is provided in the GMC Report (https://www.mouseclinic.de). 
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3 Results 
Notch receptor activation can lead to canonical downstream signaling that involves the 
association of the cleaved intracellular domain of the Notch receptor with other proteins and 
the direct binding of the complex to target gene promoter regions such as Hes1 and Hes5 
(Artavanis-Tsakonas et al., 1999). It can also lead to a non-canonical branch that involves 
the indirect activation of Hes3 (Androutsellis-Theotokis et al., 2006). This non-canonical 
branch of Notch or '' STAT3-Ser/Hes3'' was initially associated with neural stem cells. It was 
later proven to be a master regulator of cancer stem cells as well (Park et al., 2013). More 
recently, it was also found that Hes3 is expressed in the adult mouse pancreatic islet and 
regulates gene expression, cell growth and insulin release (Masjkur et al., 2014a). Insulin 
regulates Hes3 expression (Androutsellis-Theotokis et al., 2008); impaired insulin signaling is 
potentially linked to neurodegeneration and brain insulin resistance has been associated with 
Alzheimer's disease (de la Monte and Wands, 2005). 
My thesis project aims to further investigate the STAT3-Ser/Hes3 signaling axis as a tool to 
characterize the brain state in metabolic syndrome and aging. To achieve this, my 
experimental plan had three main objectives: (a) to show that Hes3 is expressed in specific 
mouse brain areas (b) to investigate if eNSCs are affected by metabolic syndrome and aging 
with the use of Hes3 as a biomarker and (c) to assess the importance and the functionality of 
the Hes3 gene in metabolic syndrome. To achieve these aims, a combination of in vivo and 
in vitro tools were utilized.  
Initially, we investigated Hes3 expression in the adult mouse brain. We used PCR to 
measure Hes3 at the mRNA expression level and immunofluorescence to detect Hes3 at the 
protein level. However, throughout this thesis, quantification of our data is mainly based on 
qPCR analysis (due to the limited specificity of the available polyclonal anti-Hes3 antibodies). 
We utilized in vivo models of aging and diabetes in an effort to address whether the brain is 
affected by metabolic syndrome. To obtain clues to the functions of Hes3, we performed a 
general phenotypic analysis of Hes3 null mice. Since Hes3 null mice revealed stress-induced 
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phenotypes before (Masjkur et al., 2016; Toutouna et al., 2016) we performed the phenotypic 
analysis under both normal and stressed conditions.  
3.1 Hes3 is expressed in the mouse brain 
To investigate Hes3 expression in the mouse brain we utilized a combination of PCR, qPCR, 
and immunofluorescence (IF) experiments. To measure Hes3 expression, we prepared RNA 
extracts from mouse brains where the olfactory bulb and all parts hind to the cortex were 
removed unless stated differently. PCR analysis showed expression of Hes3 in the 17 week 
old mice tested (Figure 3.1 B, C). We used primer sets that detect total Hes3 as well as 
primer sets that detect each of the two isoforms (Hirata et al., 2000) of Hes3 (Hes3a and 
Hes3b), demonstrating that both isoforms are expressed. 
We performed the immunofluorescence study in the area of the septo-diencephalon. We 
observed that in this area of the brain Hes3 is expressed in the outer layer of the cortex 
forming a characteristic dense layer. We defined this layer as the “Hes3 zone”. The antibody 
staining against Hes3 further confirmed the Hes3 expression in the mouse brain at the 
protein level (Figure 3.2). 
 
Figure 3.1. Hes3 is expressed in the mouse brain. (A) Canonical and non-canonical 
branches of Notch signaling induce the expression of different members of the Hes/Hey gene 
family. (B) Diagram showing the brain area used for PCR, qPCR, and Western Blot 
experiments (unless otherwise noted). PCR blots for Hes3, Hes3a, and Hes3b showing 
mRNA expression in the 17 week old mouse brain. HPRT was used as a housekeeping 
control (N=6. Each lane corresponds to a different mouse).  
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Figure 3.2. Hes3 expression in the mouse brain cortex. (A) Immunofluorescence study 
for Hes3 expression in the septodiencephalic area of the mouse brain (Bregma 1.18 to 
0.02mm). (B) Hes3 expression in the motor cortex of the mouse brain. (C) Magnified imaged 
of the Hes3 staining in the motor cortex. To measure the ‘’Hes3 zone’’ we performed 3 
measurements per image (yellow arrows). Scale bar 30µm. 
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3.2 Aging and diabetes models alter Hes3 in the brain 
Insulin is a powerful inducer of Hes3 expression. Impairment in insulin signaling has been 
widely associated with neurodegenerative disease. Aging results in lower amount of insulin in 
the CNS, which may be associated with cognitive impairment and neurodegeneration (Laron, 
2009). We therefore addressed whether Hes3 expression is altered in type 1 and type 2 
diabetes mouse models and aging. In the pancreas, the toxin streptozotocin (STZ) induces a 
powerful increase in Hes3 expression, possibly in an effort to promote regeneration of 
pancreatic islet cells (Masjkur et al., 2014a; Masjkur et al., 2016; Poser et al., 2015). Here we 
addressed whether similar effects can also be observed in the brain. STZ is used to damage 
pancreatic islet cells and produce animal models for the study of type 1 diabetes that exhibit 
reduced production and systemic circulation of insulin (Al-Awar et al., 2016). HFD-induced 
type 2 diabetes is a complex condition that involves elevated circulating insulin (an activator 
of Hes3) as well as complex inflammatory responses (some of which promote and others 
oppose Hes3 expression) (Masjkur et al., 2014a; Ohta et al., 2012). It is therefore difficult to 
predict the effect of particular HFD paradigms on brain Hes3; here we investigated this 
question using established HFD protocols. 
3.2.1 Hes3 expression decreases with age  
To assess the effect of aging on Hes3 expression we compared two groups of mice referred 
to as ''young'' (~17 weeks old) and ''old mice'' (~34 weeks old). To measure Hes3 
expression, we prepared RNA samples from brain tissue as described above (Figure 3.1 B). 
The data revealed significant reduction of Hes3 expression from 16 to 34 weeks of age. An 
additional cohort of animals confirmed the reduction in Hes3 mRNA levels from 16 to 42 
weeks of age (Reduction: Hes3a 0.12±0.04 fold, p<0.05; N=5,4 and Hes3b:0.66±0.05 fold, 
p<0.05; N=6,4). A polyclonal antibody against Hes3 further confirmed the reduction in Hes3 
expression from 16 to 34 weeks of age (Figure 3.3 B-D)  
 
3.2.2 Pancreatic islet damage by streptozotocin increases Hes3 
expression in the brain 
Consistent with published studies, mice treated with STZ exhibited increased glucose levels, 
and reduced insulin levels, demonstrating successful implementation of this animal model. In 
these mice, Hes3a and Hes3b mRNA levels in the brain were significantly increased; in 
contrast, the mRNA levels of the canonical Notch signaling targets Hes1 and Hes5 were not 
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altered (Figure 3.4). These data show that pancreatic damage leads to Hes3 expression 
changes in the brain. 
3.2.3 High Fat Diet reduces Hes3 expression in the brain 
HFD is a common approach to study aspects of obesity and metabolic dysfunction in mice 
(Islam and Loots du, 2009). We subjected the mice to HFD for different time periods 
(indicated as ''short feeding', ''intermediate feeding'', and ''long feeding'' and we measured 
changes in the Hes3 mRNA expression levels with qPCR. In both the short and long HFD 
feeding groups the mice gained BW and exhibited an increase in circulating glucose and 
insulin levels, as expected in this model of type 2 diabetes (Figure 3.5 A-C). In the short 
HFD feeding group, Hes3a, Hes3b, Hes1, but not Hes5 expression was reduced; in the long 
HFD feeding group, Hes3a and Hes3b expression showed a tendency to decrease but did 
not reach statistical significance. Again, Hes1 but not Hes5 levels also dropped (Figure 3.5 
D-E).  
Hes3 in the mouse brain is expressed in distinct plastic cell types depending on the area of 
interest; in the motor cortex Hes3 is expressed in oligodentrocyte precursors (Toutouna et 
al., 2016) and in the hypothalamus in the tanycytes of the median eminence (Nikolakopoulou 
et al., 2016). Therefore, we used a separate group of mice kept under HFD conditions for an 
intermediate time period (16 weeks), to identify particular brain areas where Hes3 mRNA 
levels are regulated. Mice under HFD gained weight as expected. From this group we 
prepared RNA samples from distinct brain areas: Hypothalamus (HPT), Cerebellum (CBL), 
and the Remaining Brain without HPT, CBL, and olfactory bulbs that we denote here as 
“RB”). In this group of mice we measured significant reductions in both Hes3a and Hes3b 
levels (Figure 3.6 A-C).  
These results show that HFD induces significant alterations in the expression of Hes3 and 
Hes1 in the brain. 
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Figure 3.3. Hes3 expression decreases with age. (A) qPCR analysis of the relative mRNA 
expression of Hes/Hey genes in young and old mice (N=3-6). (B) Diagram showing the brain 
areas used for image acquisition and Hes3 signal measurement. (C) Examples of images used 
for Hes3 quantification. The particular images correspond to the top field marked in (A). Nuclei 
are stained with DAPI and are shown in blue (Scale bar: 50µm). (D) Quantification of Hes3 
immunolabeling signal from (C). Data are presented as mean ± SEM. Mann-Whitney U test; 
*p<0.05.  
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Figure 3.4. Streptozotocin increases Hes3 expression in the mouse brain. (A,B) A single 
high dose of STZ increases blood glucose levels, and reduces insulin levels 8 weeks after 
injection, indicating the establishment of the STZ model of type 1 diabetes (N=8). (C) A single 
high dose of STZ significantly increases Hes3a and Hes3b levels in the brain (p<0.05); Hes1 
and Hes5 levels do not significantly change (N=6-7. HPRT was used as a reference gene). 
Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05. 
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Figure 3.5. HFD decreases Hes3 expression in the mouse brain. (A-C) HFD increases 
BW, blood glucose levels, and insulin levels at different time points, indicating the 
establishment of the Type II diabetes model (N=4-10; measurements were performed after 
an overnight fasting). (D) HFD (short and long feeding) regulates Hes/Hey gene expression 
(N=4-7. HPRT was used as a reference gene). Data are presented as mean ± SEM. Mann-
Whitney U test; *p<0.05.  
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Figure 3.6. HFD regulates Hes3 expression in different brain areas. (A) Diagram 
showing the dissected brain areas. (B) Average relative gene expression for Hes3a and 
Hes3b in different brain areas. (N=5-8; BR, HPT, CBL; intermediate HFD feeding; HPRT was 
used as a reference gene). (C) Heatmap of the data shown in (B). Data are presented as 
mean ± SEM. Mann-Whitney U test; *p<0.05.  
 
3.3 Common diabetes medication affect neural stem cells 
(NSCs) in the brain 
We also investigated whether common medication for metabolic related dysfunction also 
affects Hes3 expression in the adult brain. Metformin is a widely prescribed medication; its 
effects on cognition and the progression of neurodegenerative disease are not yet fully 
understood. It regulates signaling pathways that intercept with Hes3; we thus addressed the 
effect of metformin on Hes3 expression in the living brain; and in cultured NSCs to address 
the question if metformin acts on the NSCs directly.  
3.3.1 Metformin decreases Hes3 expression in the brain 
We addressed the effect of metformin on Hes3 expression in the living brain. Mice were 
given metformin in the drinking water for 8 weeks, starting at the age of 8 weeks. At the end 
of the experiment, brains were dissected and RNA preparations were made from RB, HPT, 
and CBL. HPT is involved in metabolic regulation and Hes3 is expressed in the hypothalamic 
tanycytes (Nikolakopoulou et al., 2016), Hes3 is highly expressed in the CBL although its 
roles are unknown (Hirata et al., 2001); RB would provide an overview of Hes3 regulation in 
the remaining brain areas. Metformin did not significantly affect BW gain (not fasted values); 
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fasting BW was not affected, glucose levels were significantly reduced and fasting insulin 
levels were slightly but not statistically significantly increased (Figure 3.7 A-D). Our data 
show that metformin affects the expression of multiple Hes/Hey genes in the living brain 
(Figure 3.7 E-H). Interestingly, Hes3 is significantly decreased in the hypothalamus after 
metformin treatment. 
3.3.2 Metformin opposes growth but increases Hes3 expression in 
cultured NSCs 
Metformin affects the expression of multiple Hes/Hey genes in the adult mouse brain. A 
summary of the data obtained of our in-vivo experiment described above is given in the form 
of a heat map (Figure 3.8 A). To address the direct effect of metformin on NSCs, we used 
established culture systems of primary mouse fetal NSCs (fNSCs). Dose response 
experiments demonstrated that 500µM metformin reduced cell number, 5-ethynyl-2´-
deoxyuridine (EdU) incorporation decreased, and cell morphology changed to a more 
differentiated appearance with longer processes (Figure 3.8 B-E).  
3.3.3 Exendin-4 promotes growth and increases Hes3 expression in 
cultured NSCs 
Exendin-4 (Ex-4) is another commonly used type-2 diabetes medication. We previously 
showed that it induces Hes3 expression in a cultured mouse insulinoma cell line (Masjkur et 
al., 2014a). Thus, we hypothesized that it may affect NSCs as well. Dose dependence 
experiments revealed a significant increase in the cell growth at concentrations (200nM) 
while the morphology of the cells and proliferation (as indicated via EdU staining) were not 
affected (Figure 3.10 A-D). qPCR analysis revealed increase in the Hes3 mRNA expression 
level at 72 hours similarly to the result we observed with metformin. This result suggests that 
the increase in Hes3 expression by metformin may be part of a stress response to the 
treatment. Hes5 mRNA expression levels increase as well after 72 hours treatment with Ex-4 
(Figure 3.10 F). 
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Figure 3.7. Metformin regulates Hes3 expression in vivo. (A) BW progression in mice 
treated with metformin (2g/l in the drinking water, continuously for 8 weeks), and control mice 
(normal drinking water; not fasted BW measurements; N=12). (B) BW, glucose, and insulin 
measurements in mice treated with metformin, and control mice. (N=12; measurements were 
performed after an overnight fasting). (E) Heatmap showing gene expression levels of different 
Hes/Hey genes in different areas of the brain in control and metformin-treated mice. (N=5-12; 
MET, Metformin; HPRT was used as a reference gene]. (F-H) Bar graph version of the qPCR 
analysis shown in (E). Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05.  
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Figure 3.8. Metformin affects cultured NSCs. (A) The heatmap shows average gene expression 
levels in different areas of the brain after metformin treatment for 2 months. (N=5-12; MET, 
Metformin) (B) Metformin reduces cell number (DAPI-stained nuclei counts) in a dose-dependent 
manner (N=4; 72h, 500µM). (C) Metformin (500µM) reduces EdU incorporation in vitro (N=3; 72h 
(D, E) Brightfield images of control and metformin-treated (500µM, 72 hours) primary fNSC 
cultures. Scale bar: 30 µm. Data are presented as mean ± SEM. Unpaired t-test; *p<0.05. HPRT 
was used as a reference gene. 
 
Time course experiments revealed a time-dependent increase in Hes3a and Hes3b mRNA 
levels; at 72 hours we observed increased mRNA levels of Hes3a and Hes3b but not Hes1 
or Hes5 (Figure 3.9 A, B). These data show that metformin regulates Hes3 levels in cultured 
NSCs.  
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Figure 3.9. Metformin treatment increases Hes3 mRNA expression levels. (A) Metformin 
(500µM) regulates Hes3a and Hes3b mRNA levels in vitro a time dependent manner (N=3). 
(B) Metformin (500µM) regulates Hes3a and Hes3b but not Hes1 and Hes5 mRNA levels in 
vitro (N=3, 72h). Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05. HPRT 
was used as a reference gene. 
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Figure 3.10. Exendin-4 regulates Hes3 expression in vitro. (A) Ex-4 increases cell 
number (DAPI-stained nuclei counts) in a dose-dependent manner (N=7; 72h, 200nM). (B) 
Brightfield image of primary mouse fNSC cultures treated with Ex-4 (200nM) for 72 hours (to 
compare with Figure 1.8 D). (C) Ex-4 (200nM) does not significantly alter EdU incorporation 
(N=3; 72h treatment). (D) Image examples of EdU incorporation 72 hours after treatment with 
Ex-4 (200nM). EdU was added 5 hours before cell fixation. Scale bar: 30 µm. (E) Ex-4 
(200nM) regulates Hes3a and Hes3b mRNA levels in vitro a time dependent manner (N=4). 
(F) Ex-4 (200nM, 72h) regulates Hes/Hey gene mRNA levels in cultured fNSCs (N=4). Data 
are presented as mean ± SEM. Unpaired t-test; *p<0.05. HPRT was used as a reference 
gene. 
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3.3.4 Metformin and Exendin-4 affect the STAT3-Ser/Hes3 signaling 
axis  
We performed Western Blot analysis to compare the effect of both treatments on 
components of the STAT3-Ser/Hes3 signaling axis. The results are shown in Figure 3.11. 
 
Figure 3.11. Metformin and Exendin-4 affect the STAT3-Ser/Hes3 signaling pathway 
in mouse NSC cultures. (A-C) Brightfield images of the NSC cultures in the control 
condition; after 72 hours treatment with Metformin (500 µΜ) and after 72 hours treatment 
with Exendin-4 (200nM). Scale bar 30 µm. (D) Metformin (500 µΜ, 72 hours) decreases 
phosphorylation of the STAT3 on Ser727 and AKT phosphorylation; Ex-4 (200nM, 72 
hours stimulates the phosphorylation of the STAT3 on Ser727 and increases AKT 
phosphorylation. 
 
These data show that metformin and exendin-4 regulate Hes3 levels in cultured NSCs and 
dissociate between the effects of these drugs on Hes3 levels and their effects on cell 
number. 
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3.4 Hes3 null mice exhibit a quasi-normal phenotype 
The expression of Hes3 is significantly affected by aging, diabetes, and diabetes medication. 
To obtain clues to the functions of Hes3, we performed a general phenotypic analysis of 
Hes3 null mice. Homozygous Hes3 null mice are generally healthy and breed normally 
(Hirata et al., 2001) but also have phenotypes that become obvious under stress 
(Androutsellis-Theotokis et al., 2008; Masjkur et al., 2014a; Masjkur et al., 2016; Toutouna et 
al., 2016). We performed a phenotypic analysis of the Hes3 null mice fed a normal diet (ND) 
and following a high fat diet (HFD) (Figure 3.12 A, B). We utilized a range of assays as a first 
screening test and the data are summarized in Table 1. The full report is provided at 
https://www.mouseclinic.de (Click on "phenomap" and search for project "Hes3_KO"). 
 
 
Figure 3.12. Hes3 phenotypic analysis in WT and Hes3 null mice. (A) Phenotypic 
analysis in WT and Hes3 null mice under normal conditions [Normal diet (ND): Males 
N=15,15 Females N=15,15]. (B) Phenotypic analysis in WT and Hes3 null mice under 
stressed conditions [High fat diet (HFD); N=11,9 Females N=11,11]. 
3.4.1 Phenotypic Analysis - Normal Diet (ND) 
3.4.1.1 Neurology and Nociception 
Primary phenotypic analysis revealed no major phenotypes in the Hes3 null mice. A 
summary of the data obtained in ND can be found in the upper part of the Table1. The data 
revealed slight phenotypes relevant to brain function such as a trend towards improved 
muscle function (assessed by grip strength; extensive analysis in the 
https://www.mouseclinic.de and a trend towards hyperalgesia in the Hes3 null mice 
[(assessed by the hot plate test (Figure 3.13)].  
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Figure 3.13. Female Hes3 null mice exhibit trend towards hyperalgesia. (A) WT and 
Hes3 null mice under ND were tested for nociception with the hot plate test (N=15). (B) The 
hotplate system. (C) Hes3 null females exhibit shorter first response time. (D) All mice had 
similar second reaction time. Data are presented as mean ± SEM. Mann-Whitney U test; 
*p<0.05. 
 
3.4.1.2 Age - Metabolism 
Age decreases Hes3 in the mouse brain. During the phenotypic analysis we would subject 
the mice to long-term experiments leading to ''aged'' condition. Thus, we performed glucose 
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tolerance test in young and old mice in order to assess the effect of age on metabolism in the 
Hes3 null mice. Young Hes3 null mice (9 weeks old) showed higher GTT scores than the WT 
indicating impaired glucose tolerance. Interestingly, older mice (27 weeks old) showed no big 
differences in terms of GTT scores (Figure 3.14). 
 
Figure 3.14. Hes3 null mouse phenotyping – Age related phenotypes. (A, B) Young 
Hes3 null mice showed higher GTT scores compared to WT control mice (N=12,12) in the 
glucose tolerance test. (C, D) Older mice showed no difference in the GTT scores (N=7,6). 
Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05 
 
However, ipITT in the same mice showed lower normalized glucose levels for the Hes3 null 
mice 15 minutes after insulin injection (Figure 3.15). Insulin action in the mouse is mostly 
characterized from the first fall and till the 30 minutes measurement, since the half time of 
insulin in the mouse organism is ~10minutes (Ayala et al., 2010). Thus, we consider this 
result as an indication of higher insulin sensitivity in the Hes3 null mice. In a group of mice 
analyzed at the 16 weeks of age (intermediate period of time) we observed that Hes3 null 
mice showed lower GTT scores (refer to GMC report in https://www.mouseclinic.de).  
  
 63 
 
Figure 3.15. Insulin tolerance test. Hes3 null mice showed lower normalized blood glucose 
levels 15 minutes after insulin injection. Data are presented as mean ± SEM. Mann-Whitney 
U test; *p<0.05. 
 
These data suggest interplay among Hes3, glucose metabolism, and compensatory 
mechanisms of the mouse due to the Hes3 gene deletion. These results suggest that age 
plays an important role (even at the level of a week difference) in the experimental design 
and the analysis of the obtained data.  
3.4.2 Metabolism Relevant Phenotypes – HFD challenge 
We investigated metabolism-relevant phenotypes in more detail, in males. In ND, Hes3 null 
mice behaved similarly to wild-type (WT) mice in terms of BW gain (Figure 1.16 A-C). In both 
ND and HFD, Hes3 null mice showed lower glucose levels during the course of the ipGTT 
compared to WT mice, resulting in slightly lower AUC values especially for the second part of 
the test [AUC (30-120mins)], which might indicate an improved glucose tolerance (HFD: 
Figure 3.17; ND: see https://www.mouseclinic.de). Hes3 null mice in HFD also exhibited a 
trend towards higher rectal and body surface temperature [For consistency, we show data 
from males (Mann Whitney U test; p=0.053; N=7,7)]. Two Way ANOVA analysis revealed a 
significant increase in the body temperature of WT versus KO mice when both male and 
female mice were analyzed together (p=0.036; N=14,14)] (Figure 3.17 C). 
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Figure 3.16. Hes3 null mouse phenotyping – Metabolic related phenotypes. (A, B) The 
mice groups that were tested for body weight progression in ND and HFD conditions. (C) BW 
progression in mice fed a ND (N=5, 5), or a HFD (N=11, 9) for 16 weeks. Data are presented 
as mean ± SEM. Mann-Whitney U test; *p<0.05. 
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Figure 3.17. Hes3 null mouse phenotyping – Metabolic related phenotypes. (A) WT and 
Hes3 null mice were fed a HFD for ~24 weeks. (B) Glucose tolerance test in the HFD 
challenge reveals lower GTT scores for the Hes3 null mice (N=9,11). (C) Hes3 null mice 
exhibit a trend towards higher rectal and body surface temperature than controls (N=7,7). 
Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05. 
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Table 1. Summary of phenotypic analysis. 
Screen Method Phenotype summary Hes 3 null 
NORMAL DIET   
Energy 
Metabolism 
Indirect calorimetry 
NMR 
-None 
-Trend towards increased fat content over time 
mainly in male mutants 
Behavior Open field -None 
 Acoustic startle response, PPI -None 
Neurology Modified SHIRPA,  
Auditory brain stem response 
Rotarod  
Grip strength 
-None  
-None 
-None 
-Small trend towards increased fore paw force 
Nociception Hot plate - Shorter reaction time for the first pain reaction 
in females, 
 trend towards hyperalgesia 
Dysmorphology Anatomical observation, X-ray, 
MicroCT scans (dissected 
bones) 
-None 
Cardiovascular Awake ECG 
Echocardiography 
-No clear phenotype 
-Very mild increase in septum width in systole 
(males). 
-Very mild reduction in heart rate and thus RR 
interval prolongation 
-Very mild alterations in QRS, ST and Qtdisp 
intervals (probably by chance) 
Eye Scheimpflug imaging, OCT, 
LIB, drum 
 -Slight decrease in retinal thickness (females) 
Clinical 
Chemistry 
IpGTT 
Insulin levels 
Clinical chemical analysis 
Hematology 
-IPGTT: Mild trend downwards in males and 
upwards in females for AUC values. 
-None 
-Trend towards changes in creatinine and 
fructosamine (mainly females) concentrations 
-Hematology: Slightly lower platelet distribution 
width 
Immunology Flow cytometry analysis of 
Peripheral Blood Leukocytes 
-Subtle alterations in the leukocyte 
subpopulations,  
however no evidence for pathological 
effects in the immune system: 
-increased frequency of B cells 
-decreased frequency of CD4 single positive T 
cells 
-increased frequency of CD4 CD8 double 
positive T cells 
-increased proportion of CD8 single positive T 
cells (females) 
-increased CD44 expression on CD4+ T cells 
Allergy ELISA (IgE concentration) 
TEWL 
-None 
-None 
Pathology Macro & microscopic analysis -None 
HIGH FAT DIET   
Energy 
Metabolism 
Indirect calorimetry, NMR -None 
 Body temperature -Slight increase in males and females 
 Fat mass -Mild decrease in females  
Allergy TEWL -Slight increase in females 
 Body surface temperature -None 
Clinical 
Chemistry 
IpGTT -IPGTT: Mild trend downwards in males for 
AUC values. 
  
 67 
3.4.3 Phenotypic Analysis – Molecular  
The function of Hes/Hey genes is largely unknown, as is the manner in which they regulate 
each other. To obtain information, at the molecular level, on the possible roles of Hes3 in the 
brain, we measured the expression of Hes/Hey genes in the brains of Hes3 null mice under 
ND (for 19 weeks, starting at 8 weeks of age) and Hes3 null mice under HFD (for 16 weeks, 
starting at 8 weeks of age). We prepared RNA samples from distinct areas of the mouse 
brain for all the different group of mice (WT-ND, KO-ND, WT-HFD and KO-HFD) (Figure 
3.18 A, B) and we performed qPCR experiments to identify changes in the gene expression 
levels of the Hes/Hey genes family. 
 
Figure 3.18. RNA isolation from distinct brain areas from the WT and the Hes3 null 
mouse. (A, B) We isolated RNA from distinct brain areas (indicated as ''RB'', HPT, and 
''CBL'' from mice that were fed a ND for 19 weeks or a HFD for 16 weeks. 
 
qPCR analysis revealed significant differences in the expression levels of several Hes/Hey 
genes in different areas of the brain. In contrast to the ND groups, in the HFD group we did 
not observe any significant differences in the expression of the other Hes/Hey genes 
between Hes3 null mice and wild-type controls, in any of the three brain regions. Data are 
shown in detail (per mouse, per area and per diet) in the form of a heatmap in Figure 3.19. A 
summary of the data obtained from the qPCR experiments is provided in the form of a 
heatmap in Figure 3.20. 
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Figure 3.19. Hes3 null mice exhibit altered expression of Hes/Hey genes in the brain. 
(A) Heatmap showing gene expression levels of different Hes/Hey genes in different areas of 
the brain in WT and Hes3 null mice, in ND and HFD conditions. The heat map shows values 
from individual mice (N=4-8) (B-G) Bar graph version of the qPCR analysis shown in (A). 
Data are presented as mean ± SEM. Mann-Whitney U test; *p<0.05. HPRT was used as a 
reference gene. 
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Figure 3.20. Hes/Hey gene expression profiling. Heatmap of the average qPCR gene 
expression levels of different Hes/Hey genes in WT and Hes3 null mice in the brain areas 
indicated under ND and under HFD conditions. (N=4-8). 
 
These results show that the lack of Hes3 alters the equilibrium of other Hes/Hey genes and 
that this effect is observed in ND but not HFD. We therefore conclude that Hes3 regulates 
other Hes/Hey genes in the mouse brain, in a diet-dependent manner. 
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4 DISCUSSION 
Global life expectancy has substantially increased over the last century (World Health 
Organization, 2017). This comes along with an increase in age-related conditions, such as 
neurodegenerative disease. Alzheimer's, Parkinson's, Huntington's disease, and Multiple 
sclerosis are all brain disorders, which progress with age and incorporate neuronal 
dysfunction/loss in motor, sensory, or cognitive systems. At the same time, the incidence of 
obesity and metabolic diseases have also increased over the last years, a fact that supports 
the idea that metabolic syndrome and neurodegenerative disease are highly interconnected 
(Procaccini et al., 2016). Obesity has been associated with a wide range of diseases such as 
diabetes, cardiovascular disease and liver disease; however it was recently demonstrated 
that mid-life obesity is a risk factor for eventual development of neurodegenerative disease 
such as dementia, Parkinson's and Alzheimer' disease (Abbott et al., 2002; Hassing et al., 
2009; Kivipelto et al., 2005). Thus, metabolic dysfunction affects the brain. In the new age of 
stem cell biology, it is important to address the state of endogenous neural stem cells in the 
brain and specifically how they are affected by metabolic dysfunction because these cells are 
known to play important roles in the protection of the brain from insults and its regeneration 
following damage. But the molecular mechanisms they utilize are complex, unusual, and our 
understanding of them is incomplete. 
Understanding the molecular mechanisms that mediate the effect of metabolic state on 
neural stem cells in the brain is a subject of intense study as they may hold clues for the 
progression and treatment of a variety of metabolic and degenerative diseases. The STAT3-
Ser/Hes3 Signaling Axis was first identified as a major regulator of neural stem cells and, 
subsequently, cancer stem cells. Here we discuss how this signaling cascade, with Hes3 at 
its core is affected in the case of aging and in mouse models of diabetes (Type I and Type 
II). We also investigated whether common medication (in this work we used Metformin and 
Exendin-4) for metabolic related dysfunction also affects Hes3 expression in the adult brain.  
Our data support the hypothesis that the STAT3-Ser/Hes3 Signaling Axis is a novel tool to 
characterize brain state in case of metabolic syndrome and deserves further research in the 
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context of neuroendocrinology. In this part of my thesis, I will provide additional insight into 
the mechanisms and the potential biological phenomena that may be responsible for our 
observations. 
4.1 Diabetes affects the brain 
Type 1 and type 2 diabetes as well as being overweight or obese are risk factors for 
developing cognitive impairment and dementia (recently reviewed by de la Monde (de la 
Monte, 2017) and within (Alosco and Gunstad, 2014; Fotuhi et al., 2012; J et al., 2009; 
Luchsinger et al., 2007; Pedditizi et al., 2016)). In part, this risk is thought to be due to 
aberrant insulin actions directly to the brain. Beyond stimulating glucose metabolism, insulin 
(and the related hormone IGF-1) have multiple functions in the brain, supporting the survival 
of neurons and oligodendrocytes (de la Monte and Wands, 2005), promoting synaptic 
integrity and plasticity (Chiu et al., 2008), and helping working memory and cognition (de la 
Monte, 2013). At the signal transduction level, post-mortem analysis of brains from patients 
with Alzheimer’s disease reveals perturbed signaling downstream of the insulin receptor, 
including reduced insulin and IGF-1 binding to their receptors and impaired PI3K/Akt 
signaling (Moloney et al., 2010; Rivera et al., 2005; Steen et al., 2005; Talbot et al., 2012). 
There is interest, therefore, in identifying novel molecular mechanisms downstream of the 
insulin receptor that may be perturbed in the brain of diabetes patients. 
4.2 STAT3-Ser/Hes3: a putative mediator 
STAT3-Ser/Hes3 signaling is a recently identified molecular mechanism that integrates a 
variety of signals, including insulin/PI3K/Akt and regulates NSC number in vitro and in vivo 
(Androutsellis-Theotokis et al., 2006). In cultured NSCs, insulin treatment leads to PI3K – 
dependent Akt phosphorylation and subsequent mTOR and STAT3 phosphorylation on the 
serine residue. The latter event is critical to the survival of NSCs as transfection with a 
STAT3 plasmid where the serine residue is mutated to an alanine (and, thus, cannot be 
phosphorylated) leads to cell death. Following STAT3-serine phosphorylation, transcription of 
Hes3 is elevated. Hes3 induces the expression of the NSC mitogen and neuroprotective 
cytokine sonic hedgehog, as revealed by Hes3 overexpression experiments. In vivo, various 
pharmacological treatments that induce this pathway (as measured by levels of Hes3 
expression) promote powerful and long-lasting neuronal rescue and improve motor skills in 
models of ischemic stroke and Parkinson’s disease (Androutsellis-Theotokis et al., 2006; 
Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 2009). Hes3 null mice 
exhibit reduced pancreatic regeneration (Masjkur et al., 2014a; Masjkur et al., 2016) and 
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lower levels of myelin basic protein (MBP) in the brain (Toutouna et al., 2016), suggesting 
deficits in the equilibrium between oligodendrocyte progenitors and oligodendrocytes. 
4.3 Hes3 is a special member of the Hes/Hey gene family 
Notch receptor activation can lead to canonical downstream signaling that involves the 
association of the cleaved intracellular domain of the Notch receptor with other proteins and 
the direct binding to target gene promoter regions such as Hes1 and Hes5 (Artavanis-
Tsakonas et al., 1999). It can also lead to a non-canonical branch that involves the indirect 
activation of Hes3 transcription (Androutsellis-Theotokis et al., 2006). In cultured NSCs, the 
actions of these two branches are very different. Canonical Notch leads to Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) signaling activation, 
which promotes STAT3-Tyrosine (STAT3-Tyr) phosphorylation and, thus, gliogenic 
differentiation (Kamakura et al., 2004). In contrast, non-canonical Notch signaling involving 
Hes3 transcription maintains self-renewal and promotes cell survival through a STAT3-Ser – 
dependent mechanism (Androutsellis-Theotokis et al., 2006). The two branches are 
competing as JAK-STAT activation suppresses Hes3 expression. Treatments that promote 
Hes3 expression lead to disease modification in animal models of neurological disorder 
(Androutsellis-Theotokis et al., 2006; Androutsellis-Theotokis et al., 2008; Androutsellis-
Theotokis et al., 2009). Therefore, here we focused on the regulation of Hes3 in the context 
metabolic dysfunction. 
The role of Hes3 is largely unknown. However, Hes3 is expressed in several tissues, 
including the developing and adult brain and pancreas. It has two isoforms (Hes3a and 
Hes3b), generated by distinct promoters. Hes3b is the larger of the two isoforms and the only 
one that has DNA-binding properties (Hirata et al., 2000), suggesting the possibility that the 
two isoforms have distinct functions. Thus, it is crucial to perform experiments that can 
elucidate distinct functions of Hes3a and Hes3b (e.g. Different regulation via the same 
stimulus).  
4.4 Patterns of Hes3 expression may be specific to cell 
type and microenvironment 
In this work, we assessed Hes3 regulation in different brain areas, including the 
hypothalamus, an important component of the HPA Axis controlling homeostasis, and which 
exhibits strong Hes3 expression (Nikolakopoulou et al., 2016). Specific cell types may 
regulate and utilize the two isoforms differently and future studies may address this aspect. 
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Both intrinsic (e.g., cell surface receptors leading to particular signaling pathways) and 
extrinsic (e.g., inflammatory cytokines) factors may affect Hes3 expression in each cell type. 
It is important to not group all inflammatory cytokines together when addressing their effects 
on Hes3 as they may differ greatly. Whereas many inflammatory cytokines (e.g., the 
interleukin family) activate the JAK-STAT signaling pathway and would thus be expected to 
suppress Hes3 expression, Microphage Migration Inhibitory Factor (MIF), has been shown to 
promote it via an Akt/mTOR/STAT3-Ser mechanism (Ohta et al., 2012). Therefore, the 
precise inflammatory responses activated in different disease models may contribute to the 
exact Hes3 expression patterns that we observed. A better understanding of the interaction 
between specific inflammatory responses and Hes3 may help inform drug discovery 
programs aimed at both modulating inflammation and protecting brain tissue. 
4.5 Metabolic dysfunction and diabetes medication affect 
brain Hes3 
The insulin signaling branch that leads to Hes3 activation is important for proper brain 
homeostasis. Here we addressed whether it is affected by metabolic dysfunction. Our data 
show that in models of aging, type 1 diabetes, and type 2 diabetes, Hes3 expression is 
significantly regulated in the brain. Metformin is a medication commonly used in patients with 
diabetes and other indications of metabolic dysfunction (Inzucchi et al., 2012; Wilkin, 2001). 
It affects a broad range of signaling pathways (Lei et al., 2017), including several effectors of 
Hes3 in NSCs such as IGF-1 and p38 MAPK (Androutsellis-Theotokis et al., 2006; Sun et al., 
2015). Therefore, we hypothesized that it may also regulate Hes3 in the brain. Our data 
show significant regulation of Hes3 mRNA in the brain of mice given oral metformin.  
4.5.1 Age regulates Hes3 
Hes3 expression drops significantly with age, which may be expected for a gene expressed 
in NSC and progenitor cells (Androutsellis-Theotokis et al., 2006; Androutsellis-Theotokis et 
al., 2009). The consequences of this drop are not known, however, increased Hes3 levels 
correlate with regenerative capability and improved NSC growth (Androutsellis-Theotokis et 
al., 2006; Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 2009; Salewski 
et al., 2012). The reason behind this drop is also not known; candidate regulators may 
include cytokines whose expression drops with age and which are known or predicted to 
stimulate Hes3 expression. There is more direct evidence implicating the inflammatory 
cytokine MIF. Its levels decrease with age (Mathew et al., 2013; Sauler et al., 2015) and it 
has been shown to induce Hes3 expression, via Akt and mTOR in cultured NSCs, and to 
promote their survival (Ohta et al., 2012). MIF has clinical potential as it has been associated 
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with longevity; particular long-lived mouse breeds exhibit increased levels and caloric 
restriction (an inducer of longevity) is also characterized by increased MIF levels (Miller et al., 
2002).It will be important to identify other Hes3 regulators and to decipher the role of 
decreasing Hes3 levels in aging. 
 
4.5.2 Diabetes models regulate Hes3 expression in the brain 
We used STZ to model type 1 diabetes and a HFD to model type 2 diabetes. We did not 
observe changes in Hes1 or Hes5 expression, pointing towards important roles of the non-
canonical branch of Notch signaling that involves Hes3. One could expect that because in 
cultured NSCs, insulin induces Hes3 expression (Androutsellis-Theotokis et al., 2008), STZ 
(which reduces circulating insulin levels) should reduce brain Hes3 expression. However, 
other factors such as the oxidative stress and inflammatory responses in the brain, which are 
triggered by STZ and type 1 diabetes may be responsible for the Hes3 increase (Nazem et 
al., 2015). We previously reported a similar finding in the pancreas where STZ induced 
powerful upregulation of Hes3 expression in the damaged pancreatic islets (Masjkur et al., 
2014a). 
HFD-induced type 2 diabetes is a complex condition that involves elevated circulating insulin 
(an activator of Hes3) as well as complex inflammatory responses (some of which promote 
and others oppose Hes3 expression) (Masjkur et al., 2014a; Ohta et al., 2012). It is therefore 
difficult to predict the effect of particular HFD paradigms on brain Hes3; here we investigated 
this question using established HFD protocols. HFD (short term and long term) decreased 
Hes3 expression. In addition, we performed a more detailed analysis in a subgroup of mice, 
where different areas of the brain were dissected and analyzed separately in order to 
investigate the effects of HFD on Hes3 in each specific area. In all the investigated areas 
(hypothalamus, cerebellum and rest brain) we observed a reduction in Hes3 expression with 
HFD. 
Additionally, future studies may address whether Hes3+ cells become insulin resistant after 
prolonged HFD. Taken together, these data further support the hypothesis that Hes3 is 
modulated in response to stress. 
4.5.3 Metformin regulates Hes3 expression in the brain 
Metformin is a widely used medication for type 2 diabetes, although its mechanism of action 
remains unclear. It affects a wide range of signaling pathways, making it difficult to predict 
off-target effects. In triple-negative breast cancer cell lines, metformin was shown to oppose 
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both JAK/STAT3-Tyr activity and STAT3-Ser phosphorylation (Deng et al., 2012). It is 
possible that, depending on which of the two branches of STAT3 is mostly affected, the 
outcome may either favor or oppose Hes3 expression. In addition, metformin opposes mTOR 
activation, via 5' AMP-activated protein kinase (AMPK) stimulation (Hawley et al., 2010; 
Owen et al., 2000; Rozengurt, 2014; Sinnett-Smith et al., 2013), a function that should also 
oppose Hes3 expression. Inflammatory responses triggered by metformin (as well as by type 
2 diabetes itself) (Bloom and Al-Abed, 2014; Dandona et al., 2004; Oliveira et al., 2016) 
further complicate the predictability of its effects on Hes3 expression. 
Our data with cultured NSCs show increased Hes3 expression following metformin treatment 
for 72 hours. We hypothesize that this may be, in part, due to responses to cellular stress as 
evidenced by reduced growth and enhanced differentiation.  
Ex-4 is a drug commonly prescribed to patients with type 2 diabetes. It promotes cell survival 
in the presence of toxic immunosuppressive drugs, proliferation, and even pancreatic islet 
neogenesis in various in vitro and in vivo systems (D'Amico et al., 2005; Li et al., 2005b; Park 
et al., 2006; Perfetti et al., 2000; Xu et al., 1999). We previously showed that Ex-4 also 
increases Hes3 expression in MIN6 cells (Masjkur et al., 2014a), suggesting that it may 
increase Hes3 expression in cultured NSCs without reducing cell number. Indeed, Ex-4 
increased Hes3 expression without opposing growth or inducing differentiation. This was 
expected based on the fact that Ex-4 activates signaling pathways such as Akt that lead to 
Hes3 induction (Gonzalez et al., 2005; Li et al., 2005a; Masjkur et al., 2014a; Park et al., 
2006; Song et al., 2008). Taken together, our results show that both metformin and Ex-4 
increase Hes3 expression in cultured NSCs but only metformin opposes their growth. 
Therefore, Hes3 likely does not mediate the reduced cell growth effects of metformin on 
NSCs. The observed decrease in the cell proliferation due to the metformin treatment 
indicates reduced cell growth. Thus, we hypothesize that increased Hes3 expression 
following metformin treatment may be a consequence of increased cell stress. 
The complex manner in which metformin affects NSCs directly or via inflammatory and stress 
responses may contribute to the lack of consensus regarding its potential role as a 
therapeutic agent in neurodegenerative disease (Kaneb et al., 2011; Moreira, 2014). It is 
conceivable that patients on metformin will benefit from concomitant treatments that 
modulate the inflammatory response in the brain such that Hes3 levels are maintained within 
an appropriate range. For example, promoting MIF responses while suppressing interleukin 
responses may have beneficial effects on the neural stem/progenitor population, on neurons, 
and on cognitive function. 
Metformin is currently being considered as a potential anti-aging medication (Barzilai et al., 
2016). It may be of value to assess the consequences of metformin treatments on Hes3 
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levels in different tissues and at different time points as (a) Hes3 is regulated by aging, (b) 
metformin regulates Hes3 levels, and (c) Hes3 is involved in a variety of regeneration 
paradigms, at least in the brain and pancreas. 
4.6 Hes3 phenotyping provides clues to Hes3 functions 
Hes3 null mice are healthy (Hatakeyama et al., 2004; Hirata et al., 2001), however close 
inspection revealed phenotypes such as reduced levels of MBP in the brain (Toutouna et al., 
2016). More strikingly, Hes3 null mice exhibit increased sensitivity to toxic stress and 
impaired regeneration (Masjkur et al., 2014a; Masjkur et al., 2016; Toutouna et al., 2016). A 
comprehensive phenotypic analysis confirmed the broad lack of obvious phenotypes but 
revealed several mild effects, which may prove more significant in experiments involving 
different stresses. For example, we report mild differences between wild type and Hes3 null 
mice in ipGTT, ipITT and nociception tests, under normal conditions. Hes3 null mice 
undergoing HFD exhibit a slightly higher temperature than wild types. Future studies may 
address the significance of this phenotype by studying body temperature homeostasis in cold 
room experiments as well as possible roles of Hes3 in adipose (white or brown) tissue. 
Our observation that Hes3-/- mice have alterations in the percentage of CD4+ and CD8+ T-
cells and on the expression of CD44 suggest that a detailed analysis of the effects of Hes3 
on immunological parameters may reveal additional functions of this transcription factor in 
the immune system. 
Notch signaling and, in particular, canonical [Recombining binding protein suppressor of 
hairless (Rbpj)- and Hes1-dependent] Notch signaling controls browning in the adipose 
tissue with consequences in thermogenesis (Bi et al., 2014). It will be of interest to assess 
the possible involvement of non-canonical Notch signaling (Hes3-dependent) in this process 
as well. 
Despite the lack of pronounced phenotypes in the Hes3 null mouse, qPCR analysis reveals 
widespread differences in the expression of Hes/Hey genes in the brain, under normal 
conditions. However, when mice were placed on HFD, differences between Hes3 null and 
wild type mice were not observed. It is possible that because in HFD Hes3 expression is 
reduced relative to ND, the effect of lacking Hes3 is not as pronounced. It is also possible 
that HFD regulates other Hes/Hey genes independently from Hes3 in a manner that 
overrides the genetic lack of Hes3. These results show that the lack of Hes3 alters the 
equilibrium of the other Hes/Hey genes and that this outcome is affected by diet. Whether 
this differential role of Hes3 is dependent on particular metabolic or inflammatory parameters 
is not currently known and certainly requires further investigation. 
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4.7 Hes3 and metabolic dysfunction: Are they connected? 
Our work establishes that multiple parameters of metabolic state as well as diabetes 
medication affect Hes3 expression in the brain. The scientific literature provides additional 
clues as to how brain Hes3 may be affected by other systems. Below we provide a 
conceptual model integrating these findings. 
Aging reduces Hes3 expression. The inflammatory cytokine Macrophage Migration Inhibitory 
Factor (MIF) is a positive regulator of Hes3 (Ohta et al., 2012) whose expression also drops 
with age (Mathew et al., 2013; Sauler et al., 2015) and is associated with longevity (Miller et 
al., 2002). It is possible, therefore, that as MIF drops with age this contributes to the 
reduction of Hes3 expression we observed with age. 
Insulin is another powerful inducer of Hes3 (Androutsellis-Theotokis et al., 2006; 
Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 2009). Therefore, in type 
1 diabetes models, reduced circulating insulin levels may promote a reduction in Hes3 levels 
in the brain. However, in the STZ models, cell stress caused by the damage to the organism 
may also promote an increase in brain Hes3 levels. Also, STZ-induced inflammation in the 
brain may further alter Hes3 expression. Which of these effects prevails may depend on the 
particular model used and the particular time point of the assessment of Hes3 levels. 
HFD involves initial periods of inflammation and subsequent periods of prolonged elevated 
insulin (Heydemann, 2016). The effect of the HFD-induced inflammatory response on brain 
Hes3 may depend on the precise response as some inflammatory cytokines such as 
interleukin 6 (IL-6) are both involved in diabetes mellitus (Kristiansen and Mandrup-Poulsen, 
2005) and are predicted to oppose Hes3 expression [because they activate JAK which 
opposes Hes3 expression (Androutsellis-Theotokis et al., 2006; Masjkur et al., 2014a)] 
whereas at least one other cytokine, MIF, has been demonstrated to increase Hes3 
expression levels (Ohta et al., 2012). Future studies may address how Hes3 expression is 
specifically altered by oxidative and inflammatory stress components such as oxygen 
radicals produced by the mitochondria of affected cells and activated, nuclear NF-kB. Cross-
talk between NF-kB and JAK-STAT signaling as well as between reactive oxygen species 
and JAK-STAT increases the complexity by which Hes3 may be regulated (Ahmad et al., 
2015; Grivennikov and Karin, 2010; Simon et al., 1998). 
The type 2 diabetes medication metformin has multiple effects at the signal transduction level 
(Dandona et al., 2004; Deng et al., 2012; Hawley et al., 2010; Oliveira et al., 2016; Owen et 
al., 2000; Rozengurt, 2014; Sinnett-Smith et al., 2013). One of the best described effects is 
that it opposes mTOR activity. Because mTOR is a potent activator of Hes3 expression, this 
result may explain our observation that metformin, in vivo, reduces Hes3 levels (in the 
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hypothalamus of adult mice). Metformin may also induce stress effects on target cells, and 
this could lead to an increase in Hes3 expression. Our observations using cultured NSCs 
suggest this as a possibility, as we observed a reduction in cell growth, induced 
differentiation, and an increase in Hes3 expression. 
We therefore suggest that Hes3 integrates various parameters of metabolic state and may 
serve as a biomarker for brain state in diabetes and other metabolic disorders. A schematic 
diagram summarizing how Hes3 could be integrated in research programs investigating the 
relationship metabolic dysfunction and brain condition is provided in Fig.4.1. 
 
 
 
Figure 4.1. Conceptual diagram of how Hes3 may be integrating multiple biological 
parameters. We present a hypothesis-driven schematic diagram with potential ideas as to 
how Hes3 may be integrated in research programs studying the effects of metabolic 
dysfunction to the brain. 
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5 Conclusions and Future Remarks 
Extensive research over the last years has established neural stem and progenitor cell 
populations in the adult brain as major contributors to the functionality of the nervous system 
in both the healthy and the injured state. Immature cells sense signals from the 
microenvironment of the tissue they reside in and decide if they should quiesce, proliferate, 
or differentiate. Such distinct populations of primary cells that have the potential to decide for 
their fate add to the plasticity potential of the tissue they reside in as well as its regenerative 
potential upon injury or disease. Therefore it is crucial: a) to understand the mechanisms 
which regulate the decisions of those cells and b) develop biomarkers that mark them in both 
the activated as well as in the quiescent state.  
As we extensively reported in the previous sections of this work, the STAT3-Ser/Hes3 
signaling axis regulates a variety of plastic cells such as the neural stem cells in the brain, 
the tanycytes in the hypothalamus, oligodentrocyte precursors in the motor cortex, adrenal 
precursors, pancreatic islet beta cells and cancer stem cells (Androutsellis-Theotokis et al., 
2006; Masjkur et al., 2014a; Masjkur et al., 2014c; Nikolakopoulou et al., 2016; Park et al., 
2013; Toutouna et al., 2016). Insulin was shown to be one of the major regulators of this 
signaling cascade (Androutsellis-Theotokis et al., 2008). This immediately pointed to the 
possibility that metabolic dysfunction may affect brain Hes3. 
With this work we aim to provide a further understanding of the interconnection between 
brain state and metabolic disease, which is characterized by insulin signaling impairment. 
We showed that brain Hes3 levels drop with age and that they are regulated in diabetes 
mouse models. In addition, we showed that common medication prescribed for metabolic 
diseases regulates Hes3 in vivo and in vitro. Full phenotypic analysis of the Hes3 null mouse 
line revealed phenotypes relevant to the neurological system, the immune system, and 
metabolism. At the molecular level, we showed that Hes3 deletion results in significant 
changes in the expression of other Hes/Hey genes under normal diet conditions.  
Last but not least, it was evident that Hes3 expression decreases with aging, as it is 
expected for a biomarker for NSCs. In addition, the results of the phenotypic analysis were 
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highly dependent on the age of the mice, which stresses the importance of experimental 
design in order to reveal phenotypes due to Hes3 deletion.  
Taken together, we propose Hes3 as a novel biomarker of the state of eNSCs of relevance 
to metabolic related conditions. This work introduces a new molecular mechanism and cell 
subpopulation that regulates the state of the brain in metabolic dysfunction. 
This PhD thesis project established that metabolic dysfunction, medication, and aging 
regulate a key component of the STAT3-Ser/Hes3 Signaling Axis, providing a new molecular 
mechanism by which peripheral systems affect the brain. Because this molecular mechanism 
is very important to brain homeostasis and repair, the data open up opportunities to 
understand multiple important medical issues in the fields of diabetes, aging, and 
neurodegenerative disease. Future experiments may address how perturbation of Hes3 
expression (using the heterozygous and homozygous Hes3 null mice, or by 
pharmacologically increasing Hes3 expression as previously described (Androutsellis-
Theotokis et al., 2006; Androutsellis-Theotokis et al., 2008; Androutsellis-Theotokis et al., 
2009) may affect brain tissue damage in diabetes models, and cognition in the context of 
aging and metformin administration. Our phenotypic analyses with the Hes3 null mice reveal 
immune phenotypes and a full characterization of the affected cell populations could shed 
additional light on how Hes3 may regulate the immune system and how this in turn, via the 
secretion of specific cytokines, may affect Hes3 itself. 
Within the vast complexity of this molecular mechanism, we clearly showed, using extensive 
in vitro and in vivo models, that a key component of the STAT3-Ser/Hes3 Signaling Axis is 
directly relevant to type 1 and type 2 diabetes mellitus, metformin treatment and aging. 
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